褪黑素对阿霉素抗乳腺癌作用影响及其机制的体内外研究
|
摘要
乳腺癌作为一种女性常见病,在世界范围内女性恶性肿瘤性疾病中发病率居第一位,死亡率位居第二。据2007年统计,全世界每年约有7.9万新发乳腺癌病例,占全部女性恶性肿瘤总数的21%。全世界乳腺癌年均发病率为30.30/10万,世界人口调整率为32.97/10万。其中近60%的乳腺癌新发病例在发达国家。虽然乳腺癌的发病率在世界范围内差异较大,但整体均呈上升趋势,发病年龄也渐呈年轻化趋势。对于发展中国家的我们也不例外,在一些大城市,乳腺癌已位居妇女癌症中第一位,也成为女性恶性肿瘤的头号杀手。因而提高乳腺癌的疗效和治愈率已成为迫在眉睫的问题。
以手术、化疗、放疗和内分泌治疗相结合的综合治疗模式已成为当前乳腺癌的标准治疗。随着全身性疾病观念的确立,全身化疗在综合治疗中所起的作用越来越引起重视,在2008版NCCN指南中,可见绝大篇幅内容涉及化疗的治疗规范。其中以阿霉素为代表的葸环类细胞毒药物仍然扮演着不可获却得角色,它对于保证疗效、改善预后和减少高危患者的复发起着至关重要的作用。然而,临床不得不面对的两个问题是:(1)阿霉素的耐药成为影响疗效的巨大障碍,无论天然耐药还是获得性耐药都直接影响了它作为一线药物的应用。尽管多年来对其耐药机制进行了大量研究,目前仍未见到经济、安全又有效的耐药逆转药物普及于临床。(2)阿霉素的心脏毒性作为剂量限制性毒性也严重影响了其在临床的广泛使用,累积剂量的限制也迫使无法进一步提高剂量强度;它所造成心脏不可逆损伤也严重影响患者治疗后的生活质量。在生活质量要求越来越高的今天,对这些问题的解决要求也就更为迫切。
研究已经证实褪黑素与化疗同时应用能明显改善化疗所致的血小板减少症、免疫抑制、有助于肿瘤患者的睡眠从而减轻焦虑,它能显著提高晚期肿瘤患者的生活质量。褪黑素的器官保护作用也是近年来研究的热点,尤其有研究发现褪黑素能减轻葸环类药物所致的心脏氧化损伤,无疑对拓展临床上葸环类药物的应用带来了新的希望。此外很早就有研究报道,褪黑素能够提高顺铂、氟脲嘧啶等多种化疗药物的疗效,更有临床研究发现肺癌、胃肠道癌症患者常规化疗同时伍用褪黑素,其疗效较对照组显著提高。鉴于以上,我们设计了本课题:分别从分子、细胞水平和动物实验水平探讨了褪黑素对阿霉素抗乳腺癌作用及其作用机制。
第一部分褪黑素对阿霉素抗乳腺癌作用的影响及其机制
目的:探讨褪黑素对ER+的MCF-7和ER-的MDA-MB-231细胞系的抑制作用以及对阿霉素抗乳腺癌作用的影响及其机制。
方法:(1)应用四甲基偶氮唑蓝(MTT法)检测不同浓度褪黑素和阿霉素分别对MCF-7和MDA-MB-231细胞的抑制作用,检测生理浓度和药理浓度的褪黑素对阿霉素抗癌作用的影响。(2)应用流式细胞学方法分别检测不同浓度褪黑素、阿霉素以及两药不同浓度联用时对细胞周期分布和凋亡的影响。(3)应用Western blotting法检测生理浓度、药理浓度褪黑素、阿霉素和药理浓度褪黑素联合阿霉素对细胞中P53和bcl-2蛋白的表达。
结果:(1)褪黑素对MCF-7和MDA-MB-231乳腺癌细胞均有不同程度的抑制作用,且呈剂量和时间依赖性。阿霉素对MCF-7和MDA-MB-231的IC50值分别为0.62ug/ml和1.0ug/ml,二者相比有显著性差异(p＜0.05)。生理浓度(10~(-9)mol/L)和药理浓度(10~(-5)mol/L)褪黑素孵育后可使MCF-7的IC50值由0.62ug/ml分别降为0.59ug/ml和0.42ug/ml,前者与孵育前相比未见显著性差异(P＞0.05),后者差异显著(P＜0.01)。阿霉素对MDA-MB-231的IC50为1.00ug/ml,生理和药理浓度的褪黑素孵育后分别降为0.85ug/ml和0.47ug/ml,与孵育前相比前者未见显著性差异(P＞0.05),后者差异显著(P＜0.01)。
(2)流式细胞学检测结果:生理浓度的褪黑素即可对MCF-7具有明显的G0/G1期阻滞作用和凋亡促进作用(P＜0.05),且具有浓度依赖性。而生理浓度褪黑素对MDA-MB-231的周期阻滞和凋亡作用并不明显(P＞0.05),药理浓度方能显示出明显作用(P＜0.05)。阿霉素对该两种细胞均能抑制增殖和促进凋亡,随浓度增高增殖指数降低(P＜0.05),而凋亡率不增加(P＞0.05)。生理浓度褪黑素联合阿霉素对MCF-7的作用与相应浓度的单纯阿霉素相比,其增殖指数明显降低(P＜0.05),而凋亡率并不增加(P＞0.05)。药理浓度褪黑素联合阿霉素与相应浓度单纯阿霉素组比较,使MCF-7增殖指数下降,凋亡率亦明显增加。增殖指数与阿霉素有浓度依赖性(P＜0.05),而凋亡随浓度未显示出明显变化(P＞0.05)。对MDA-MB-231,生理浓度褪黑素仅与高浓度阿霉素联用时能使其增殖指数降低(P＜0.05),对凋亡率未见显著影响(P＞0.05)。药理浓度褪黑素与低浓度阿霉素联用对MDA-MB-231增殖指数未见明显影响(P＞0.05),而凋亡率显著增加(P＜0.05)。进一步研究发现增殖指数随阿霉素浓度增加而降低(P＜0.05),凋亡率变化不明显(P＞0.05)。
(3)两种乳腺癌细胞株中均呈P53蛋白低表达、bcl-2蛋白高表达;生理浓度褪黑素即可显著增高MCF-7细胞P53蛋白并降低BCL-2蛋白表达,并有剂量依赖性(P＜0.01),而对MDA-MB-231细胞中两种蛋白的表达并无显著影响;药理浓度褪黑素均可显著提高两种细胞的P53蛋白,降低bcl-2蛋白表达(P＜0.01);药理浓度褪黑素联合褪黑素对两种细胞中两蛋白表达与药理浓度褪黑素组相比均未见显著性差异(P＞0.05);阿霉素对两种蛋白表达未见明显影响(P＞0.05)。
结论:(1)细胞培养发现体外褪黑素对ER+和ER-乳腺癌细胞系均有抑制作用,呈现明显的剂量依赖性,但敏感程度不同,提示除雌激素通路外,褪黑素对乳腺癌的抑制作用可能还存在其他机制;(2)生理浓度褪黑素(10~(-9)mol/L)对阿霉素的抗癌作用未见明显影响,药理浓度(10~(-5)mol/l)以上褪黑素表现出对阿霉素明显的增敏作用;(3)阿霉素较低浓度时,凋亡促进作用是褪黑素增敏机制的一部分,随着阿霉素浓度的提高,褪黑素的细胞毒增敏机制占主要地位;(4)药理浓度褪黑素能提高乳腺癌细胞P53蛋白表达并降低bcl-2蛋白表达,P53和bcl-2通路至少是其凋亡机制的一部分;对高浓度阿霉素增敏作用中凋亡通路似乎不是主要的。
第二部分:褪黑素逆转人乳腺癌细胞MCF-7/ADM对阿霉素耐药的作用机制。
目的:探讨生理浓度(10~(-9)mol/L)和药理浓度(≥10~(-5)mol/L)褪黑素对耐阿霉素乳腺癌细胞系MCF-7/ADM的逆转作用及其机制。
方法(1)应用四甲基偶氮唑蓝(MTT)法检测经不同浓度的褪黑素孵育后,阿霉素对MCF-7/ADM细胞系半数抑制浓度IC50的改变。(2)在电镜下观察单用阿霉素(20ug/ml)以及药理浓度的褪黑素(10~(-5)mol/l)孵育后再应用阿霉素(20ug/ml),MCF-7/ADM细胞超微结构的变化。(3)应用分光光度法测定MCF-7/ADM和MCF-7/s细胞内GSH水平以及经不同浓度褪黑素孵育后MCF-7/ADM和MCF-7/s细胞内GSH水平变化。
结果:(1)褪黑素孵育前阿霉素作用于MCF-7/ADM的IC50值为24.41ug/ml。经生理浓度(10~(-9)mol/l)的褪黑素孵育后阿霉素IC50值为20.92ug/ml,两者经比较未见显著性差异(P=0.356)。经药理浓度分别为10~(-5)mol/L和10~(-3)mol/L的褪黑素孵育后阿霉素作用于MCF-7/ADM的IC50值分别成为12.25ug/ml和10.46ug/ml,与孵育前阿霉素作用于MCF-7/ADM的IC50(24.41ug/ml)相比,均具有显著性差异(P＜0.01)。(2)与单纯应用阿霉素(20ug/ml)相比,电镜下均可观察到经药理浓度(10~(-5)mol/l)的褪黑素孵育后再应用阿霉素(20ug/ml)对细胞的损伤更为严重。(3)经分光光度法测得MCF-7/ADM细胞内GSH水平明显高于MCF-7/s,生理浓度褪黑素并不能使MCF=7/ADM和MCF-7/s细胞内GSH水平明显降低(P=0.965),而药理浓度的褪黑素可以显著降低MCF-7/ADM和MCF-7/s细胞内GSH水平且具有一定的浓度依赖性(p＜0.01)。
结论:生理浓度的褪黑素对MCF-7/ADM的耐药未见明显影响,药理浓度的褪黑素对MCF-7/ADM的耐药性具有较明显逆转作用,其逆转机制可能与褪黑素对细胞内GSH水平的调控有关。
第三部分:褪黑素联合阿霉素治疗乳腺癌大鼠的活体内研究
目的:探讨体内应用褪黑素对阿霉素抗乳腺癌作用的影响,整体评价褪黑素对阿霉素的抗癌作用的机制。
方法:(1)应用SD大鼠亚硝基甲脲腹腔2次注射法制备ER+乳腺癌大鼠模型;(2)成瘤模型鼠随机分为空白对照组、溶媒组、阿霉素组、褪黑素组、褪黑素联合阿霉素组,按要求处理后观察各组大鼠的一般状态、1月存活率;(3)各组部分大鼠处理后处死分别取瘤体、心脏,光镜和电镜下观察各组心脏形态学改变。瘤体称重,免疫组化检测E-钙粘蛋白的表达,电镜下观察各组细胞损伤情况。结果:(1)采用亚硝基甲脲2次腹腔注射法制备SD大鼠乳腺癌模型成功,成瘤率91.5%,成瘤时间为注射结束后16-18周;光镜下观察肿瘤病理切片显示为黏液腺癌,免疫组化示ER表达呈阳性。(2)褪黑素组和褪黑素联合阿霉素组大鼠生活状态好于其它几组,阿霉素组生活状态最差;褪黑素组和褪黑素联合阿霉素组1月存活率分别为14/14和11/14,经比较未见显著性差异(P＜0.05),并且优于其它几组。阿霉素组(5/16)与空白对照组(4/16)比较未见明显差别(P＞0.05);
(3)空白对照组、溶媒组和褪黑素组瘤体重量未见显著性差别(P＞0.05),褪黑素联合阿霉素组瘤体重量显著低于阿霉素组和褪黑素组(P＜0.01):从大体、光镜和电镜下均可观察到褪黑素联合阿霉素组大鼠心脏损伤明显轻于阿霉素组;大体上褪黑素联合阿霉素组和褪黑素组肿瘤包膜清晰,与周围正常组织分界较明显;光镜和电镜下可见褪黑素联合阿霉素组肿瘤细胞损伤程度重于阿霉素组;心肌免疫组化测定褪黑素和褪黑素联合阿霉素组E-钙黏蛋白强表达,而空白对照组、溶媒组和阿霉素组未见E-钙黏蛋白明显表达。
结论:(1)亚硝基甲脲2次腹腔注射法能诱发SD大鼠产生ER+乳腺癌,成瘤率高且符合要求,缺点是周期较长;(2)褪黑素能显著改善乳腺癌大鼠的生活质量,抑瘤作用不明显可能与观察期尚短有关(3)褪黑素能显著减轻阿霉素所致心脏毒性,并增强其抑瘤作用;(4)褪黑素可能通过促进E-钙黏蛋白表达而发挥抑制肿瘤侵袭的作用。
Breast cancer is one of the most common malignant diseases.Now the morbidity is first and the mortality is second in female malignant tumor in world.According to statistics in 2007,there are 79,000 new cases per year, which is 31%of total number of female malignant tumor.Every year,the average morbidity of breast cancer is 30.30/100,000,and the population standardized rate is 32.97/100,000 in world.60%of new cases are in developed country.Even though the diversity of morbidity is great,the tendency is climbing,the age of onset is promoting younger staff.As one of the developing country,we are not exception.Breast cancer has become the most common malignant diseases in woman,and the number one of killer to female.Thus it is the immense problem to increase therapeutic effect and cure rate.The combined therapy mode including operation,chemotherapy, radiotherapy and endocrine therapy has become the standard one.With the establishment of concept that breast cancer is a kind of systemic disease, people pay more and more attention to the chemotherapy.In NCCN guide of 2008 edition,most of the content involve in chemotherapy.Adriamycin,as one member of anthracene nucleus cytotoxic drug,plays the indispensable part in treating breast cancer.which exerts important role in ensuring effect,improving prognosis and decreasing recurrence especially for high risk ones.however we have to face two questions:(1) As one of the first line drugs,the drug-resistance of adriamycin,regardless of natural or acquiered one,has a direct influence on its application.In spite of many study on the mechanism of drug-resistance,there are no drugs to reverse it and be used in clinical generally.(2) cardiotoxicity is the dose-restricted toxicity of adrimycin,which has a great effect on the general application:many patients suffering from heart disease have to give up it,and greater dose intensity become impossible.Also the inreversible damage of heart caused by adriamycin has a bad influence on patients' quality of life,which seems more urgent today.
Melatonin(MLT) has been proven to counteract chemotherapy toxicity such as:thrombocytopenia,immunosuppression,insomnia and anxiety,to significantly improve the quality of life with advanced solid tumor patients in poor clinical status.The organ protection is also one of the hot topic,especially that melatonin can abate the cardiac damage caused by adriamycin,which will make for expanding application of them.Besides there are reports that melatonin maybe improve the curative effect of cytotoxic drugs such as cisplatin and flurouracil,and clinical research has proved that the therapic effect in chemotherapy plus melatonin group is better than that of common chemotherapy group.In view of above,we do the experiment which investigate the effect of melatonin on adriamycin from molecule,cell and in vivo level.
PartⅠ:Study on effect and mechanism of melatonin on antitumor effect of adriamyein
Objective:To study the inhibition of melatonin on MCF-7(ER+) and MDA-MB-231(ER-),as well as the effect and mechanism of melatonin on antitumor role of adriamycin.
Methods:(1) MTT was applied to check the inhibition of different concentrations of melatonin and adriamycin,and observed the effect of physiological and pharmacological concentrations of melatonin on antitumous effect of adriamycin.(2) FCM was used to detect the cell cycle distribution and apoptosis of different groups.(3) Western blotting was utilized to detect the expression of P53 and bcl-2 protein of groups.
Results:(1) MTTmethod showed that melatonin have antiproliferation effect on MCF-7 and MDA-MB-231 by dose and time dependence.The IC50 value of MCF-7 and MDA-MB-231 for adrimycin were 0.62ug/ml and 1.00ug/ml,and there were significant difference between them.The IC50 value dropped to 0.59ug/ml and 0.42ug/ml while these cells were incubated respectively with physiological concentrations(10~(-9)mol/l) and pharmacological(10~(-5)mol/l) concentrations of melatonin,resulted in no significant difference existing between before and after cultured with Physiological concentrations(10~(-9)mol/l) of melatonin,but significant difference be observed with pharmacological(10-~5mol/1) concentrations of melatonin.The IC50 value of MDA-MB-231 for adriamycin was 1.00ug/ml, They dropped to 0.85ug/ml and 0.47ug/ml when the cells were incubated respectively with Physiological concentrations(10~(-9)mol/l) and pharmacological(10~(-5)mol/l) concentrations of melatonin,the difference of the former was not significant and that of the latter was significant compared with the IC50 before being cultured.
(2) The results of FCM:Physiological concentrations of melatonin has significant G0/G1 cell cycle block and apoptosis effect on cell line MCF-7 by dose dependence(P＜0.05).The effect of same concentrations was not so clearly for MDA-MB-231(P＞0.05),that of pharmacological concentration was significant.Adriamycin exerts its antiproliferative and apoptosis promotion effects on two cell lines.The proliferation index(PI) kept dropping with the melatonin concentrations(P＜0.05),but the apoptosis rate changed little.Compared to the same concentrations of adriamycine,the PI of MCF-7 was decreased(P＜0.05) and the apoptosis rate was not increased (P＞0.05) by physiological concentrations of melatonin plus adriamycin,on the other hand,the PI was decreased and the apoptosis rate was increased by pharmacological concentrations of melatonin plus adriamycin.For MDA-MB-231 cell line,the same results were observed only at high concentrations adriamycin plus physiological concentrations of melatonin,and the PI was not changed(P＞0.05) and apoptosis index was increased(P＜0.05) by pharmacological concentrations of melatonin plus low concentrations of adriamycin,the PI was significantly decreased with the adriamycin(P＜0.05),and the apoptosis index was not(P＞0.05).
(3) The two cell lines showed p53 low expression and bcl-2 high expression.For MCF-7,physiological concentrations of melatonin could increase p53 and decrease bcl-2 expression by dose dependence(P＜0.05) For MDA-MB-231,physiological concentrations of melatonin has no effect on two protein,Pharmacological concentrations of melatonin upregulated p53 and downregulated bcl-2 of two cell lines,but there were no significant difference between melatonin plus adriamycin and melatonin groups(P＞0.05). Adramycin has no effect on the expression of two protein(P＞0.05).
Conclusion:(1) melatonin inhibit proliferation of ER+ and ER-breast cancer cell lines by dose dependent in.The diffrence of sensitiveness degree shows that there is other mechanism except for estrogen passageway.(2) physiological concentrations of melatonin has no significantly effect on the anticancer action of adriamycin,pharmacological concentrations of melatonin or higher concentrations showed sensitization for adriamycin.(3) Apoptosis was one part of the sensitization of melatonin at low concentrations of adriamycin,the cytotoxic sensitization become more important at high concentration level.(4) Pharmacological concentrations of melatonin increased p53 and decrease bcl-2 protein expression of breast cancer cells. p53 and bcl-2 passageway are at least one part of apoptosis mechanism.The sensitization of melatonin for high concentrations of adriamycin may not involve in p53 and bcl-2 expression.
PartⅡ:the reverse effect and mechanism of melatonin on breast carcinoma cell line MCF-7/ADM resistant to adriamycin
Objective:To investigate the reverse effect and the mechanism of physiological(10~(-9)mol/1) and pharmacological(≥10~(-5)mol/l) concentrations of melatonin on cell line MCF-7/ADM or adriamycin before resistant to sdriamycin.
Method:MTT was applied to test the changes in IC50 value of cell line MCF-7/ADM or adriamycin before and after incubated with melatonin. Electron microscope was used to observe the changes in morphology and ultrastructures in the cell line MCF-7/ADM incubated only with adriamycin (20ug/ml) and the cells incubated with pharmacological concentrations of melatonin(10-5mol/l) plus adriamycin(20ug/ml).Spectrophotometry was applied to determine the level of intracellular GSH in cell line MCF-7/ADM and MCF-7/s,as well as the variation of intracellular GSH in two cell lines be incubated with different concentrations of melatonin.
Results:MTT method showed that the IC50 value of cell line MCF-7/ADM for adriamycin before culturing with melatonin was 24.41ug/ml and the IC50 of cell line MCF-7/ADM for adriamycin incubated with physiological concentrations of melatonin(10~(-9)mol/L) was 20.92ug/ml,with no significant difference.The IC50 value were 12.25ug/ml and 10.46ug/ml about the cell line MCF-7/ADM cultured with 10~(-5)mol/L and 10~(-3)mol/L melatonin,respectively,between them having significant difference(P＜0.01). The damage of cell line MCF-7/ADM incubated with pharmacological concentrations of melatonin(10~(-5)mol/L) plus adriamycin(20ug/ml) was more severe than that of the cell line cultured only with adriamycin(20ug/ml).The level of intracellular GSH in cell line MCF-7/ADM was higher than that in the cell line MCF-7/s,which was not decreased significantly by physiological (10~(-9)mol/L) concentrations of melatonin(p=0.695),but was significantly decreased by the pharmacological concentrations of melatonin(≥10~(-5)mol/L). The down-regulating effect of melatonin on the level of intracellular GSH in cell lines MCF-7/ADM and MCF-7/s was dose-depended(p＜0.01).
Conclusion:The physiological concentrations of melatonin have no influence on the drug resistance of the cell line MCF-7/ADM.The pharmacological concentrations of melatonin have reverse effect on the drug resistance of the cell line MCF-7/ADM.The reverse mechanism is probably related with the regulation of melatonin on the level of intracellular GSH in tumor cells.
PartⅢStudy on melatonin plus adriamycin treat breast carcinoma rat in vivo.
Objective:To investigate the effect of melatonin on antitumor action of adriamycin in vivo,To evaluate the influence of melatonin plus adriamycin on breast cancer wholly.
Method:(1) The N-nitroso-N-methylurea(NMU)-induced ER+ rat mammary tumor model was made by 2 times intraperitoneal injection.(2) mammary tumor tats were divided into Blank,Dissolvant,Adriamycin, and Melatonin plus adriamycin groups,to observed the life status and one month survival rates.(3) To observe the morphology change of tumor and heart of rats of groups under light microscope and electron microscope.To weigh the tumor and detect E-cadherin expression by immunohistochemistry method.To observe the damage of tumor cells and myocardium cells under electron microscope.
Results:(1) The method of 2 times N-nitroso-N-methylurea(NMU) intraperitoneal injection is successful.The achievement ratio was 91.5%.The time of tumor emergence was 16-18 weeks after injection.The pathological section showed mucinous adenocarcinoma under light microscope and ER-positive by immunohistochemistry method.(2) The life status of Melatonin and Melatonin plus adriamycin groups was better than that of the others,and that of Adriamycin group seemed worst.The one month survival rate of melatonin and melatonin plus adriamycin groups were respective 14/14 and 11/14,there were no significant difference between two groups (P＜0.05),and better than the others.but no significant difference exist between Adriamycin and Blank group.(3) There was no difference of tumor weight among Blank,Dissolvant and Melatonin(P＞0.05),the tumor weight of Melatonin plus adriamycin group was lower than that of Adriamycin and Melatonin group(P＜0.01).The damage of heart of rat in Melatonin plus adriamycin was more remissive than that of Adriamycin group by appearance, light microscope and electron microscope.The peplos of tumor in Melatonin plus adfiamycin and Melatonin groups seemed clearly and the demarcation was obviously between tumor and normal tissue.The damage of tumor cells in Melatonin plus adriamycin group was more severe than that in Adriamycin group.The expression of E-cadherin showed obviously expression in MLT and Melatonin plus adriamycin group,there was no expression of E-cadherin in Blank,Dissolvant and Adriamycin groups.
Conclusion:(1) The method of 2 times intraperitoneal injection of N-nitroso-N-methylurea(NMU) is successful.The achievement ratio can meet requirement.The cycle time of tumor emergence seems too long.(2) melatonin can improve the quality of life of tumor rats.That the oncostatic effect seems not so obviously is related with shorter observation time.(3) melatonin alleviates heart damage induced by adriamycin and has sensitization on adriamycin.(4) melatonin may inhibit tumor invasion by decreasing the expression of E-cadherin.
以手术、化疗、放疗和内分泌治疗相结合的综合治疗模式已成为当前乳腺癌的标准治疗。随着全身性疾病观念的确立,全身化疗在综合治疗中所起的作用越来越引起重视,在2008版NCCN指南中,可见绝大篇幅内容涉及化疗的治疗规范。其中以阿霉素为代表的葸环类细胞毒药物仍然扮演着不可获却得角色,它对于保证疗效、改善预后和减少高危患者的复发起着至关重要的作用。然而,临床不得不面对的两个问题是:(1)阿霉素的耐药成为影响疗效的巨大障碍,无论天然耐药还是获得性耐药都直接影响了它作为一线药物的应用。尽管多年来对其耐药机制进行了大量研究,目前仍未见到经济、安全又有效的耐药逆转药物普及于临床。(2)阿霉素的心脏毒性作为剂量限制性毒性也严重影响了其在临床的广泛使用,累积剂量的限制也迫使无法进一步提高剂量强度;它所造成心脏不可逆损伤也严重影响患者治疗后的生活质量。在生活质量要求越来越高的今天,对这些问题的解决要求也就更为迫切。
研究已经证实褪黑素与化疗同时应用能明显改善化疗所致的血小板减少症、免疫抑制、有助于肿瘤患者的睡眠从而减轻焦虑,它能显著提高晚期肿瘤患者的生活质量。褪黑素的器官保护作用也是近年来研究的热点,尤其有研究发现褪黑素能减轻葸环类药物所致的心脏氧化损伤,无疑对拓展临床上葸环类药物的应用带来了新的希望。此外很早就有研究报道,褪黑素能够提高顺铂、氟脲嘧啶等多种化疗药物的疗效,更有临床研究发现肺癌、胃肠道癌症患者常规化疗同时伍用褪黑素,其疗效较对照组显著提高。鉴于以上,我们设计了本课题:分别从分子、细胞水平和动物实验水平探讨了褪黑素对阿霉素抗乳腺癌作用及其作用机制。
第一部分褪黑素对阿霉素抗乳腺癌作用的影响及其机制
目的:探讨褪黑素对ER+的MCF-7和ER-的MDA-MB-231细胞系的抑制作用以及对阿霉素抗乳腺癌作用的影响及其机制。
方法:(1)应用四甲基偶氮唑蓝(MTT法)检测不同浓度褪黑素和阿霉素分别对MCF-7和MDA-MB-231细胞的抑制作用,检测生理浓度和药理浓度的褪黑素对阿霉素抗癌作用的影响。(2)应用流式细胞学方法分别检测不同浓度褪黑素、阿霉素以及两药不同浓度联用时对细胞周期分布和凋亡的影响。(3)应用Western blotting法检测生理浓度、药理浓度褪黑素、阿霉素和药理浓度褪黑素联合阿霉素对细胞中P53和bcl-2蛋白的表达。
结果:(1)褪黑素对MCF-7和MDA-MB-231乳腺癌细胞均有不同程度的抑制作用,且呈剂量和时间依赖性。阿霉素对MCF-7和MDA-MB-231的IC50值分别为0.62ug/ml和1.0ug/ml,二者相比有显著性差异(p＜0.05)。生理浓度(10~(-9)mol/L)和药理浓度(10~(-5)mol/L)褪黑素孵育后可使MCF-7的IC50值由0.62ug/ml分别降为0.59ug/ml和0.42ug/ml,前者与孵育前相比未见显著性差异(P＞0.05),后者差异显著(P＜0.01)。阿霉素对MDA-MB-231的IC50为1.00ug/ml,生理和药理浓度的褪黑素孵育后分别降为0.85ug/ml和0.47ug/ml,与孵育前相比前者未见显著性差异(P＞0.05),后者差异显著(P＜0.01)。
(2)流式细胞学检测结果:生理浓度的褪黑素即可对MCF-7具有明显的G0/G1期阻滞作用和凋亡促进作用(P＜0.05),且具有浓度依赖性。而生理浓度褪黑素对MDA-MB-231的周期阻滞和凋亡作用并不明显(P＞0.05),药理浓度方能显示出明显作用(P＜0.05)。阿霉素对该两种细胞均能抑制增殖和促进凋亡,随浓度增高增殖指数降低(P＜0.05),而凋亡率不增加(P＞0.05)。生理浓度褪黑素联合阿霉素对MCF-7的作用与相应浓度的单纯阿霉素相比,其增殖指数明显降低(P＜0.05),而凋亡率并不增加(P＞0.05)。药理浓度褪黑素联合阿霉素与相应浓度单纯阿霉素组比较,使MCF-7增殖指数下降,凋亡率亦明显增加。增殖指数与阿霉素有浓度依赖性(P＜0.05),而凋亡随浓度未显示出明显变化(P＞0.05)。对MDA-MB-231,生理浓度褪黑素仅与高浓度阿霉素联用时能使其增殖指数降低(P＜0.05),对凋亡率未见显著影响(P＞0.05)。药理浓度褪黑素与低浓度阿霉素联用对MDA-MB-231增殖指数未见明显影响(P＞0.05),而凋亡率显著增加(P＜0.05)。进一步研究发现增殖指数随阿霉素浓度增加而降低(P＜0.05),凋亡率变化不明显(P＞0.05)。
(3)两种乳腺癌细胞株中均呈P53蛋白低表达、bcl-2蛋白高表达;生理浓度褪黑素即可显著增高MCF-7细胞P53蛋白并降低BCL-2蛋白表达,并有剂量依赖性(P＜0.01),而对MDA-MB-231细胞中两种蛋白的表达并无显著影响;药理浓度褪黑素均可显著提高两种细胞的P53蛋白,降低bcl-2蛋白表达(P＜0.01);药理浓度褪黑素联合褪黑素对两种细胞中两蛋白表达与药理浓度褪黑素组相比均未见显著性差异(P＞0.05);阿霉素对两种蛋白表达未见明显影响(P＞0.05)。
结论:(1)细胞培养发现体外褪黑素对ER+和ER-乳腺癌细胞系均有抑制作用,呈现明显的剂量依赖性,但敏感程度不同,提示除雌激素通路外,褪黑素对乳腺癌的抑制作用可能还存在其他机制;(2)生理浓度褪黑素(10~(-9)mol/L)对阿霉素的抗癌作用未见明显影响,药理浓度(10~(-5)mol/l)以上褪黑素表现出对阿霉素明显的增敏作用;(3)阿霉素较低浓度时,凋亡促进作用是褪黑素增敏机制的一部分,随着阿霉素浓度的提高,褪黑素的细胞毒增敏机制占主要地位;(4)药理浓度褪黑素能提高乳腺癌细胞P53蛋白表达并降低bcl-2蛋白表达,P53和bcl-2通路至少是其凋亡机制的一部分;对高浓度阿霉素增敏作用中凋亡通路似乎不是主要的。
第二部分:褪黑素逆转人乳腺癌细胞MCF-7/ADM对阿霉素耐药的作用机制。
目的:探讨生理浓度(10~(-9)mol/L)和药理浓度(≥10~(-5)mol/L)褪黑素对耐阿霉素乳腺癌细胞系MCF-7/ADM的逆转作用及其机制。
方法(1)应用四甲基偶氮唑蓝(MTT)法检测经不同浓度的褪黑素孵育后,阿霉素对MCF-7/ADM细胞系半数抑制浓度IC50的改变。(2)在电镜下观察单用阿霉素(20ug/ml)以及药理浓度的褪黑素(10~(-5)mol/l)孵育后再应用阿霉素(20ug/ml),MCF-7/ADM细胞超微结构的变化。(3)应用分光光度法测定MCF-7/ADM和MCF-7/s细胞内GSH水平以及经不同浓度褪黑素孵育后MCF-7/ADM和MCF-7/s细胞内GSH水平变化。
结果:(1)褪黑素孵育前阿霉素作用于MCF-7/ADM的IC50值为24.41ug/ml。经生理浓度(10~(-9)mol/l)的褪黑素孵育后阿霉素IC50值为20.92ug/ml,两者经比较未见显著性差异(P=0.356)。经药理浓度分别为10~(-5)mol/L和10~(-3)mol/L的褪黑素孵育后阿霉素作用于MCF-7/ADM的IC50值分别成为12.25ug/ml和10.46ug/ml,与孵育前阿霉素作用于MCF-7/ADM的IC50(24.41ug/ml)相比,均具有显著性差异(P＜0.01)。(2)与单纯应用阿霉素(20ug/ml)相比,电镜下均可观察到经药理浓度(10~(-5)mol/l)的褪黑素孵育后再应用阿霉素(20ug/ml)对细胞的损伤更为严重。(3)经分光光度法测得MCF-7/ADM细胞内GSH水平明显高于MCF-7/s,生理浓度褪黑素并不能使MCF=7/ADM和MCF-7/s细胞内GSH水平明显降低(P=0.965),而药理浓度的褪黑素可以显著降低MCF-7/ADM和MCF-7/s细胞内GSH水平且具有一定的浓度依赖性(p＜0.01)。
结论:生理浓度的褪黑素对MCF-7/ADM的耐药未见明显影响,药理浓度的褪黑素对MCF-7/ADM的耐药性具有较明显逆转作用,其逆转机制可能与褪黑素对细胞内GSH水平的调控有关。
第三部分:褪黑素联合阿霉素治疗乳腺癌大鼠的活体内研究
目的:探讨体内应用褪黑素对阿霉素抗乳腺癌作用的影响,整体评价褪黑素对阿霉素的抗癌作用的机制。
方法:(1)应用SD大鼠亚硝基甲脲腹腔2次注射法制备ER+乳腺癌大鼠模型;(2)成瘤模型鼠随机分为空白对照组、溶媒组、阿霉素组、褪黑素组、褪黑素联合阿霉素组,按要求处理后观察各组大鼠的一般状态、1月存活率;(3)各组部分大鼠处理后处死分别取瘤体、心脏,光镜和电镜下观察各组心脏形态学改变。瘤体称重,免疫组化检测E-钙粘蛋白的表达,电镜下观察各组细胞损伤情况。结果:(1)采用亚硝基甲脲2次腹腔注射法制备SD大鼠乳腺癌模型成功,成瘤率91.5%,成瘤时间为注射结束后16-18周;光镜下观察肿瘤病理切片显示为黏液腺癌,免疫组化示ER表达呈阳性。(2)褪黑素组和褪黑素联合阿霉素组大鼠生活状态好于其它几组,阿霉素组生活状态最差;褪黑素组和褪黑素联合阿霉素组1月存活率分别为14/14和11/14,经比较未见显著性差异(P＜0.05),并且优于其它几组。阿霉素组(5/16)与空白对照组(4/16)比较未见明显差别(P＞0.05);
(3)空白对照组、溶媒组和褪黑素组瘤体重量未见显著性差别(P＞0.05),褪黑素联合阿霉素组瘤体重量显著低于阿霉素组和褪黑素组(P＜0.01):从大体、光镜和电镜下均可观察到褪黑素联合阿霉素组大鼠心脏损伤明显轻于阿霉素组;大体上褪黑素联合阿霉素组和褪黑素组肿瘤包膜清晰,与周围正常组织分界较明显;光镜和电镜下可见褪黑素联合阿霉素组肿瘤细胞损伤程度重于阿霉素组;心肌免疫组化测定褪黑素和褪黑素联合阿霉素组E-钙黏蛋白强表达,而空白对照组、溶媒组和阿霉素组未见E-钙黏蛋白明显表达。
结论:(1)亚硝基甲脲2次腹腔注射法能诱发SD大鼠产生ER+乳腺癌,成瘤率高且符合要求,缺点是周期较长;(2)褪黑素能显著改善乳腺癌大鼠的生活质量,抑瘤作用不明显可能与观察期尚短有关(3)褪黑素能显著减轻阿霉素所致心脏毒性,并增强其抑瘤作用;(4)褪黑素可能通过促进E-钙黏蛋白表达而发挥抑制肿瘤侵袭的作用。
Breast cancer is one of the most common malignant diseases.Now the morbidity is first and the mortality is second in female malignant tumor in world.According to statistics in 2007,there are 79,000 new cases per year, which is 31%of total number of female malignant tumor.Every year,the average morbidity of breast cancer is 30.30/100,000,and the population standardized rate is 32.97/100,000 in world.60%of new cases are in developed country.Even though the diversity of morbidity is great,the tendency is climbing,the age of onset is promoting younger staff.As one of the developing country,we are not exception.Breast cancer has become the most common malignant diseases in woman,and the number one of killer to female.Thus it is the immense problem to increase therapeutic effect and cure rate.The combined therapy mode including operation,chemotherapy, radiotherapy and endocrine therapy has become the standard one.With the establishment of concept that breast cancer is a kind of systemic disease, people pay more and more attention to the chemotherapy.In NCCN guide of 2008 edition,most of the content involve in chemotherapy.Adriamycin,as one member of anthracene nucleus cytotoxic drug,plays the indispensable part in treating breast cancer.which exerts important role in ensuring effect,improving prognosis and decreasing recurrence especially for high risk ones.however we have to face two questions:(1) As one of the first line drugs,the drug-resistance of adriamycin,regardless of natural or acquiered one,has a direct influence on its application.In spite of many study on the mechanism of drug-resistance,there are no drugs to reverse it and be used in clinical generally.(2) cardiotoxicity is the dose-restricted toxicity of adrimycin,which has a great effect on the general application:many patients suffering from heart disease have to give up it,and greater dose intensity become impossible.Also the inreversible damage of heart caused by adriamycin has a bad influence on patients' quality of life,which seems more urgent today.
Melatonin(MLT) has been proven to counteract chemotherapy toxicity such as:thrombocytopenia,immunosuppression,insomnia and anxiety,to significantly improve the quality of life with advanced solid tumor patients in poor clinical status.The organ protection is also one of the hot topic,especially that melatonin can abate the cardiac damage caused by adriamycin,which will make for expanding application of them.Besides there are reports that melatonin maybe improve the curative effect of cytotoxic drugs such as cisplatin and flurouracil,and clinical research has proved that the therapic effect in chemotherapy plus melatonin group is better than that of common chemotherapy group.In view of above,we do the experiment which investigate the effect of melatonin on adriamycin from molecule,cell and in vivo level.
PartⅠ:Study on effect and mechanism of melatonin on antitumor effect of adriamyein
Objective:To study the inhibition of melatonin on MCF-7(ER+) and MDA-MB-231(ER-),as well as the effect and mechanism of melatonin on antitumor role of adriamycin.
Methods:(1) MTT was applied to check the inhibition of different concentrations of melatonin and adriamycin,and observed the effect of physiological and pharmacological concentrations of melatonin on antitumous effect of adriamycin.(2) FCM was used to detect the cell cycle distribution and apoptosis of different groups.(3) Western blotting was utilized to detect the expression of P53 and bcl-2 protein of groups.
Results:(1) MTTmethod showed that melatonin have antiproliferation effect on MCF-7 and MDA-MB-231 by dose and time dependence.The IC50 value of MCF-7 and MDA-MB-231 for adrimycin were 0.62ug/ml and 1.00ug/ml,and there were significant difference between them.The IC50 value dropped to 0.59ug/ml and 0.42ug/ml while these cells were incubated respectively with physiological concentrations(10~(-9)mol/l) and pharmacological(10~(-5)mol/l) concentrations of melatonin,resulted in no significant difference existing between before and after cultured with Physiological concentrations(10~(-9)mol/l) of melatonin,but significant difference be observed with pharmacological(10-~5mol/1) concentrations of melatonin.The IC50 value of MDA-MB-231 for adriamycin was 1.00ug/ml, They dropped to 0.85ug/ml and 0.47ug/ml when the cells were incubated respectively with Physiological concentrations(10~(-9)mol/l) and pharmacological(10~(-5)mol/l) concentrations of melatonin,the difference of the former was not significant and that of the latter was significant compared with the IC50 before being cultured.
(2) The results of FCM:Physiological concentrations of melatonin has significant G0/G1 cell cycle block and apoptosis effect on cell line MCF-7 by dose dependence(P＜0.05).The effect of same concentrations was not so clearly for MDA-MB-231(P＞0.05),that of pharmacological concentration was significant.Adriamycin exerts its antiproliferative and apoptosis promotion effects on two cell lines.The proliferation index(PI) kept dropping with the melatonin concentrations(P＜0.05),but the apoptosis rate changed little.Compared to the same concentrations of adriamycine,the PI of MCF-7 was decreased(P＜0.05) and the apoptosis rate was not increased (P＞0.05) by physiological concentrations of melatonin plus adriamycin,on the other hand,the PI was decreased and the apoptosis rate was increased by pharmacological concentrations of melatonin plus adriamycin.For MDA-MB-231 cell line,the same results were observed only at high concentrations adriamycin plus physiological concentrations of melatonin,and the PI was not changed(P＞0.05) and apoptosis index was increased(P＜0.05) by pharmacological concentrations of melatonin plus low concentrations of adriamycin,the PI was significantly decreased with the adriamycin(P＜0.05),and the apoptosis index was not(P＞0.05).
(3) The two cell lines showed p53 low expression and bcl-2 high expression.For MCF-7,physiological concentrations of melatonin could increase p53 and decrease bcl-2 expression by dose dependence(P＜0.05) For MDA-MB-231,physiological concentrations of melatonin has no effect on two protein,Pharmacological concentrations of melatonin upregulated p53 and downregulated bcl-2 of two cell lines,but there were no significant difference between melatonin plus adriamycin and melatonin groups(P＞0.05). Adramycin has no effect on the expression of two protein(P＞0.05).
Conclusion:(1) melatonin inhibit proliferation of ER+ and ER-breast cancer cell lines by dose dependent in.The diffrence of sensitiveness degree shows that there is other mechanism except for estrogen passageway.(2) physiological concentrations of melatonin has no significantly effect on the anticancer action of adriamycin,pharmacological concentrations of melatonin or higher concentrations showed sensitization for adriamycin.(3) Apoptosis was one part of the sensitization of melatonin at low concentrations of adriamycin,the cytotoxic sensitization become more important at high concentration level.(4) Pharmacological concentrations of melatonin increased p53 and decrease bcl-2 protein expression of breast cancer cells. p53 and bcl-2 passageway are at least one part of apoptosis mechanism.The sensitization of melatonin for high concentrations of adriamycin may not involve in p53 and bcl-2 expression.
PartⅡ:the reverse effect and mechanism of melatonin on breast carcinoma cell line MCF-7/ADM resistant to adriamycin
Objective:To investigate the reverse effect and the mechanism of physiological(10~(-9)mol/1) and pharmacological(≥10~(-5)mol/l) concentrations of melatonin on cell line MCF-7/ADM or adriamycin before resistant to sdriamycin.
Method:MTT was applied to test the changes in IC50 value of cell line MCF-7/ADM or adriamycin before and after incubated with melatonin. Electron microscope was used to observe the changes in morphology and ultrastructures in the cell line MCF-7/ADM incubated only with adriamycin (20ug/ml) and the cells incubated with pharmacological concentrations of melatonin(10-5mol/l) plus adriamycin(20ug/ml).Spectrophotometry was applied to determine the level of intracellular GSH in cell line MCF-7/ADM and MCF-7/s,as well as the variation of intracellular GSH in two cell lines be incubated with different concentrations of melatonin.
Results:MTT method showed that the IC50 value of cell line MCF-7/ADM for adriamycin before culturing with melatonin was 24.41ug/ml and the IC50 of cell line MCF-7/ADM for adriamycin incubated with physiological concentrations of melatonin(10~(-9)mol/L) was 20.92ug/ml,with no significant difference.The IC50 value were 12.25ug/ml and 10.46ug/ml about the cell line MCF-7/ADM cultured with 10~(-5)mol/L and 10~(-3)mol/L melatonin,respectively,between them having significant difference(P＜0.01). The damage of cell line MCF-7/ADM incubated with pharmacological concentrations of melatonin(10~(-5)mol/L) plus adriamycin(20ug/ml) was more severe than that of the cell line cultured only with adriamycin(20ug/ml).The level of intracellular GSH in cell line MCF-7/ADM was higher than that in the cell line MCF-7/s,which was not decreased significantly by physiological (10~(-9)mol/L) concentrations of melatonin(p=0.695),but was significantly decreased by the pharmacological concentrations of melatonin(≥10~(-5)mol/L). The down-regulating effect of melatonin on the level of intracellular GSH in cell lines MCF-7/ADM and MCF-7/s was dose-depended(p＜0.01).
Conclusion:The physiological concentrations of melatonin have no influence on the drug resistance of the cell line MCF-7/ADM.The pharmacological concentrations of melatonin have reverse effect on the drug resistance of the cell line MCF-7/ADM.The reverse mechanism is probably related with the regulation of melatonin on the level of intracellular GSH in tumor cells.
PartⅢStudy on melatonin plus adriamycin treat breast carcinoma rat in vivo.
Objective:To investigate the effect of melatonin on antitumor action of adriamycin in vivo,To evaluate the influence of melatonin plus adriamycin on breast cancer wholly.
Method:(1) The N-nitroso-N-methylurea(NMU)-induced ER+ rat mammary tumor model was made by 2 times intraperitoneal injection.(2) mammary tumor tats were divided into Blank,Dissolvant,Adriamycin, and Melatonin plus adriamycin groups,to observed the life status and one month survival rates.(3) To observe the morphology change of tumor and heart of rats of groups under light microscope and electron microscope.To weigh the tumor and detect E-cadherin expression by immunohistochemistry method.To observe the damage of tumor cells and myocardium cells under electron microscope.
Results:(1) The method of 2 times N-nitroso-N-methylurea(NMU) intraperitoneal injection is successful.The achievement ratio was 91.5%.The time of tumor emergence was 16-18 weeks after injection.The pathological section showed mucinous adenocarcinoma under light microscope and ER-positive by immunohistochemistry method.(2) The life status of Melatonin and Melatonin plus adriamycin groups was better than that of the others,and that of Adriamycin group seemed worst.The one month survival rate of melatonin and melatonin plus adriamycin groups were respective 14/14 and 11/14,there were no significant difference between two groups (P＜0.05),and better than the others.but no significant difference exist between Adriamycin and Blank group.(3) There was no difference of tumor weight among Blank,Dissolvant and Melatonin(P＞0.05),the tumor weight of Melatonin plus adriamycin group was lower than that of Adriamycin and Melatonin group(P＜0.01).The damage of heart of rat in Melatonin plus adriamycin was more remissive than that of Adriamycin group by appearance, light microscope and electron microscope.The peplos of tumor in Melatonin plus adfiamycin and Melatonin groups seemed clearly and the demarcation was obviously between tumor and normal tissue.The damage of tumor cells in Melatonin plus adriamycin group was more severe than that in Adriamycin group.The expression of E-cadherin showed obviously expression in MLT and Melatonin plus adriamycin group,there was no expression of E-cadherin in Blank,Dissolvant and Adriamycin groups.
Conclusion:(1) The method of 2 times intraperitoneal injection of N-nitroso-N-methylurea(NMU) is successful.The achievement ratio can meet requirement.The cycle time of tumor emergence seems too long.(2) melatonin can improve the quality of life of tumor rats.That the oncostatic effect seems not so obviously is related with shorter observation time.(3) melatonin alleviates heart damage induced by adriamycin and has sensitization on adriamycin.(4) melatonin may inhibit tumor invasion by decreasing the expression of E-cadherin.
引文
1 高列 许荣焜。褪黑素抗肿瘤机制的研究进展。生理科学进展 2001,32(2):160-162
2 Samuel Cos MD,Alicia Gonza'lez,Carlos Mart(?)nez-Campa Estrogen-signaling pathway:A link between breast cancer and melatonin oncostatic actions o[J]Cancer Detection and Prevention 2006,30:118-128
3 Cos S,Blask DE,Lemus-Wilson A,et al.Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture.[J]Pineal Res 1991,10:36-42.
4 蔡晓宏,赵晏,刘鸿。褪黑素对人小细胞肺癌NCIH446细胞的抑制作用.[J]中国药理学通报。2000,16(5):593-594
5 白艳红1,赵晏2,蔡晓宏,褪黑素对人胃腺癌SGC27901细胞的抑制作用。[J]西安医科大学学报。2002,23(2):144-146
6 Morgan PJ,Barrett P,Howell HE,et al.Melatonin receptor:Location molecular pharmacology and physiological significance.[J]Neurochem Int,1994,24:101-146
7 Winczyk K,Pawlikowski M,Lawnicka H,et al.Effect of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-2-yl)methyl]propanamide on murine colon 38 cancer growth in vitro and in vivo.[J]Neuroendocrinol Lett,2002,23(Suppll):50-4
8 段小娴.bcl-2基因家族对细胞凋亡的调控.中国医学文摘.肿瘤学,2001,15(1):80
9 籍敏,王全红.bcl-2在乳腺癌中的表达及意义.[J]山西医科大学学报.2007,38(4):337-338
10 Gee JM,Robertson JF,Ellis IO,et al.Immunocytochemical localization of BCL-2 protein in human breast cancer and its relationship to a series of prognostic markers and response to endocrine therapy.Int J Cancer,1994,59:619-28
11 M.D.Mediavilla,S.Cos and E.J.Sanchez-Barcelo.Melatonin increase P53and p21WAF1 expression in MCF-7 human breast cancer cells in vitro Life Sciences,1999,65(4):415-420
12 孙晓杰,吴琦.细胞凋亡相关基因P53和bcl-2在乳腺癌中的表达.[J]中国现代医学杂志。2002,12(5):72-73
13 Yoo YM,Yim SV,Kim ss,et al.Melatonin suppresses NO-induced apoptosis via induction of Bcl-2 expression in PGT-beta immortalized pineal cells.[J]Pineal Res,2002,33(3):146-150
14 Sainz RM,Mayo JC,Uria H,et al.The pineal neurohormone melatonin prevents in vivo and in invitro apoptosis in thymcytes.[J]Pineal Res,1995,19:178-188
1 Patricia S'anchez-Su'arez,Patricia Ostrosky-Wegman,Francisco Gallegos-Hern'andez,et al.DNA damage in peripheral blood lymphocytes in patients during combined chernotherapy for breast cancer[J].Mutation Research 2008,640(1-2):8-15
2 P.Lissoni.Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms [J].Pathologie Biologic 2007,55(3-4):201-204
3 Go¨ksel Sener,Nermina Jahovic,Osman Tosun,et al,Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats.Life Sciences[J].2003,74(5):563-572
4 Aysel G,Ozlem Y,Meryem C,et al.Melatonin protects against epirubicin-induced cardiotoxicity[J].Acta histochemical 2007,109(1):52-60
5 王忠强,郑启昌,黄文广,等.褪黑素、顺铂协同抑制人肝癌细胞SMMC-7721的机制研究[J].华中科技大学学报(医学版),2004,33(5):569-572
6 吴琛珩,王树人,刘漪沦,等.恶性肿瘤组织的氧化还原态及其抗氧化能力的改变[J].中国病理生理杂志,2005,21(11):2160-2165
7 韩晓群,李著华,王树人,等.细胞内GSH耗竭逆转人乳腺癌耐药细胞株MCF-7/ADM对阿霉素的耐药性[J].四川生理科学杂志,2005;27(4):152-154
8 韩晓群,李著华,张敬各,等.降低细胞内GSH浓度对乳腺癌细胞阿霉素敏感性的影响[J].四川大学学报(医学版),2007;38(5):770-774
9 Albert W,Hans-Christian C,Peter M.A,et al.Prooxidant activity of melatonin promotes fas-induced cell death in human leukemic Jurkat cells[J].FEBS Letters,2001,502(3):127-131
10 Barlow-Walden LR,Reiter RJ,Abe M,et al.Melatonin stimulates brain glutathione peroxidase activity[J].Neurichem Int,1995,26(5):497-502
11 Kumaraguruparan R,Subapriya R,Viswanathan P,et al.Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast[J].Clin Chim Acta,2002,325(1-2):165-170
12 Cullen JJ,Mitros FA,Oberley LW.Expression of antioxidant enzymes in diseases of the human pancreas:another link between chronic pancreatitis and pancreatic cancer[J].Pancreas,2003,26(1):23-27
13 Bostwick DG,Alexander EE,Singh R,et al.Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer[J].Cancer,2000,89(1):123-134
14 Kolanjiappan K,Ramachandran CR,Manoharan S.Biochemical changes in tumor tissues of oral cancer patients[J].Clin Biochem,2003,36(1):61-65
15 Rudin CM,Yang Z,Schumaker LM,et al.Inhibition of glutathione synthesis reverses Bcl-2 mediated cisplatin resistance[J].Cancer Res,2003,63(2):312-318
1 S.R.Teplitzkya,f,T.L.Kiefere,f,Q.Cheng,et al.Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid.[J]Cancer Letters 2001,168:155-163
2 Dagar S,Sekosan M,Rubinstein I,et al.Detection of VIP receptors in MNU-induced breast cancer in rats:implications for breast cancer targeting[J].Breast Cancer Res Treat,2001,65(1):49-54
3 WeiW,Shen YX,DaiM,Chen Q.Effects and mechanisms of melatonin on immune responses in mice of different months[J].Acta Pharmacol Sin,2003,24(7):719-723
4 许建宁,许建平.褪黑素与肿瘤防治的研究进展。国外医学卫生学分册,1999,26(2):78-80
5 Maria P.Jonesa,Melissa A.Melan,et al.Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner.[J].Cancer Letters 2000;151:133-143
6 Ana I.Esquifinoa,S.R.Pandi-Perumalb,et al.Circadian organization of the immune response:A role for melatonin.[J]Clinical and Applied Immunology Reviews 2004,4:423-433
7 周学武,国安,罗春芬,等.褪黑素对大鼠肝缺血再灌注损伤的保护作用研究[J].浙江医学,2006,28(8):642-644
8 Tsuda T,Ide M,Iigo M.Influence of season and of temperature,photoperiod and subcutaneous melatonin infusion on the glomerular filtration rate ofewes.[J].Pineal Res,1995,19:166-172
9 Bubenik GA.Localization,physiological significance and possible clinical implication of gast rointestinal melatonin.[J]Biol Signals Recept,2001,10:350-366
10 周良玉,张钦,康二虎.褪黑素对大鼠肠缺血/再灌注损伤保护作用的实验研究[J].实用医技杂志,2006,13(11):1810-1812
11 李源,郑延松,臧益民。褪黑素对氧化损伤培养心肌细胞的保护作用。[J].第四军医大学学报,2002,23(22),2060-62
12 韦开福,林英忠,马业新.褪黑素对大鼠缺血再灌注后心脏功能的影响[J].右江民族医学院学报,2006,28(6):914-916
13 周文峰,明章银,向继洲.褪黑素对大鼠失血性休克心肌的保护作用及对MEK/ERK通路的影响.[J].医药导报,2007,6(5)469-472
14 P.DZI EGIEL,Z.JETHON,E.SUDER,M.Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.[J]Exp Toxic Pathol.2002,53:433-439
15 Aysel Guven,Ozlem Yavuz,Meryem Cam,Melatonin protects against epirubicin-induced cardiotoxicity.[J]Acta histochemica.2007,109:52-60
16 Josefa Leona,Dario Acun(?)-Castroviejo,et al.Melatonin and mitochondrial function.[J].Life Sciences 2004,75:765-790
17 Cos S,Fern(?)ndez R,G(u|¨)ezmes A,S(?)nchez-Barcel(?)EJ.Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.[J]Cancer Res 1998,58:4383-90
18 Cos S,Fern(?)ndez R.Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells.[J]Pineal Res 2000,29:166-71
19 Garc(?)a-Pedrero JM,del Rio B,Mar(?)nez-Campa C,Muramatsu M,Lazo PS,Ramos S.Calmodulin is a selective modulator of estrogen receptors.[J]Mol Endocrinol 2002,16:947-60
20 Erkan Yurtcu,Yildiz Guney,Mehmet Ali Ergun.et al.Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007,31:1144-1149
1 何炜,李晓晔,石鑫,等.褪黑素的生理活性研究进展[J].医药导报,2006,25(6):556-558
2 Reiter RJ,Guerrero JM,Escames G,et al.Prophylactic actions of melatonin in oxidative neurotoxicity[J].Ann N Y Acad Sci,1997,825(2):70-78
3 Okatani Y,Wakatsuki A,Kaneda C,et al.Melatonin increase activities of glutathione peroxidase and superoxide dismutas in fetal rat brain[J].J Pineal Res,2000,28(2):89-96
4 Pieri C,MarraM,Moroni F,et al.Melatonin protects LDL from oxidation but does not prevent the apolipop rotein derivatization[J].B iochem B iophys Res Comm un,1996,222(2):256-260
5 Mayo JC,Sainz RM,Antolin I,et al.Melatonin regulation of antioxidant enzyme gene expression[J].Cell M ol Life Sci,2002,59(2):1706-1713
6 Rodriguez C,Mayo JC,Sainz RM,et al.Regulation of antioxidant enzymes:A significant role for melatonin[J].J Pineal Res,2004,36(1):1-9
7 Aust S,Thalhammer T,Humpeler S,et al.The melatonin receptor subtype MT 1 is expressed in human gallbladder epithelia[J].J Pineal Res,2004,36(1):43-48
8 Erkan Yurtcu,Yildiz.Guney,Mehmet Ali Ergun.et al.Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007(31)1144-1149
9 Reiter RJ,Acuna-Castroviejo D,Tan DX,et al Mechanisms for the protective actions of melatonin in the central nervous system[J].Ann N Y Acad Sci,2002,895:200 -215
10 GeoffriauM,Brun J,Chazot G,et al.The physiology and pharmacology Of melatonin in humans[J].Horm Res,1998,49(3-4):136-141
11 Konakchieva R,Mitev Y,Almeida OF,et al.Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothlamic-p ituitary-adrenal axis in the rat[J].N euroendocrinology,1998,67(3):171-180
12 Zeitzer JM,AyasNT,Shea SA,et al.Absence of detectable melatonin and p reservation of cortisol and thyrotrop in rhythms in tetrap legia[J].J Clin EndocrinolM etab,2000,85(6):2189-2196
13 LechnerO,Dietrich H,Oliveira SA,et al.Altered circadian rhythms of the stress hormone and melatonin response in lupusp rone MRL /MP fas(Ip r) mice[J].J Autoimmun,2000,14(4):325-333.
14 Kostoglou-Athanassiou I,Treacher DF,WheelerMJ,et al.Melatonin administration and pituitary hormone secreton[J].Clin Endocrinol,1998,48(1):31-37
15 Reiter R J,Tan D X,Terron M P,et al.Melatonin and its metabolites:new findings regarding their production and their radical scavenging actions [J].Acta Biochem Pol,2007,54(1):1291
16 Hardeland R,Pandi-Perumal S R,Cardinali D P.Molecules in focus:Melatonin[J].Int J Biochem Cell Biol,2006,38:313-3161
17 赵浩淼,李作孝,刘广益.褪黑激素与脑保护[J].医学综述,2006,12(10):596-598
18 王东吉,武凡,武延隽 褪黑素对大鼠脑缺血再灌注损伤及胞浆型磷脂酶A2蛋白表达的影响[J]中华老年心脑血管病杂志2007,9(4)272-275
19 李源1,郑延松1,臧益民 褪黑素对氧化损伤培养心肌细胞的保护作用。[J].第四军医大学学报,2002;23(22),2060-62
20 韦开福,林英忠,马业新.褪黑素对大鼠缺血再灌注后心脏功能的影响[J].右江民族医学院学报,2006,28(6):914-916
21 周文峰,明章银,向继洲.褪黑素对大鼠失血性休克心肌的保护作用及对MEK/ERK通路的影响.[J].医药导报,2007,6(5)469-472
22 Rafael Bruck,Hussein Aeed,Yona Avni et al.Melatonin inhibits nuclear factor kappa B activation and oxidativestress and protects against thioacetamide induced liver damage in rats.[J].Journal of Hepatology, 2004,40:86-93
23 周学武,金国安,罗春芬,等.褪黑素对大鼠肝缺血再灌注损伤的保护作用研究[J].浙江医学,2006,28(8):642-644
24 叶根深1,马勇2,魏伟褪黑素对CCl4诱导大鼠肝纤维化模型肝星状细胞凋亡和功能的影响.[J].安徽医科大学学报 2007,42(2):183-185
25 Lang U,Aubert ML,Sizonenko PC.Location of melatonin receptors[J].Paediatr Res,1981,15:80
26 Tsuda T,Ide M,Iigo M.Influence of season and of temperature,photoperiod and subcutaneous melatonin infusion on the glomerular filtration rate of ewes.[J].Pineal Res,1995,19:166-172
27 Daniels WM,Reiter RJ,Melchiorri D,et al.Melatonin counteracts lipid peroxidation induced by carbon tetrachloride but does not restore glucose-6 phosphate activity.[J]Pineal Res,1995,19:1-6
28 Bubenik GA.Localization,physiological significance and possible clinical implication of gast rointestinal melatonin.[J]Biol Signals Recept,2001,10:350-366
29 Sener-Muratoglu G,Paskaloglu K,Arbak S,et al.Protective effect of famotidine,omeprazole,and melatonin against acetylsalicylic acid-induced gastric damage in rat s.[J]Dig Dis Sci,2001,46:318-330
30 Ganguly K,Kundu P,Banerjee A,et al.Hydrogen Peroxidemediated downregulation of mat rix metalloprotease-2 in indomet hacininduced acute gastric ulceration is blocked by melatonin and other antioxidants.[J]Free Radic Biol Med,2006,41:911-925
31 Brzozowski T,Konturek PC,Zwirska-Korczala K,et al.Importance of t he pineal gland,endogenous prostaglandins and sensory nerves in t he gastroprotective actions of cent ral and peripheral melatonin against st ress-induced damage.[J]Pineal Res,2005,39:375-385
32 Brzozowska I,Konturek PC,Brzozowski T,et al.Role of prostaglandins,nitric oxide,sensory nerves and gastrin in acceleration of ulcer healing by melatonin and it s precursor,L-tryptophan.J Pineal Res,2002,32:149-162
33 周良玉,张钦,康二虎.褪黑素对大鼠肠缺血/再灌注损伤保护作用的实验研究[J].实用医技杂志,2006,13(11):1810-1812
34 张慧,张立斌,刘志民.褪黑素对高糖条件下牛主动脉内皮细胞保护作用的实验研究[J].解放军医学杂志.2003,28(3):225-227
35 Wang WZ,Fang XH,Stephenson LL,et al.Microcirculatory effects of melatonin in rat skeletal muscle after prolonged ischemia[J]J Pineal Res.2005,39(1):57-65
36 张慧,张玉西.褪黑素对高糖条件下牛主动脉内皮细胞NO S 活性和iNO S mRNA表达的影响.[J]东南国防医药,2007:9(2)95-97
37 Markowska M,Mrozkowiak A,Pawlak J,Skwarlo-Sonta K.Intracellar second messagers involved in melatonin signal transduction in chicken splenocytes in vitro[J].J Pineal Res,2004,37(3):207-212
38 Wei W,Shen YX,DaiM,Chen Q.Effects and mechanisms of melatonin on immune responses in mice of different months[J].Acta Pharmacol Sin,2003,24(7):719-723
39 Li JH,Yu JP,Yu HG,Xu XM,Yu LL,Liu J,et al.Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in ratswith colitis[J].Mediators Inflamm,2005,31(4):185-193
40 Maestroni GJ.The immunotherapeutic potential of melatonin[J].Expert Op in Investig Drugs,2001,10(3):467-476
41 Moore CB,Siopes TD.Melatonin enhances cellular and humoral immune responses in the Japanese quail(Coturnix coturnix japonica) via an opiatergic mechanism[J].Gen Comp Endocrinol,2003,131(3):258-263
42 Blickenstaff RT,Brandstadter SM,Reddy S,et al.Potential radioprotective agents:1.Homologues of melatonin.[J]Pharm Sci 1994,83:216-218
43 Vijayalaxmi,Meltz ML,Reiter RJ,et al.Melatonin and protection from whole-body irradiation:Survival studies in mice.[J]Mutat Res 1999,425:21-27
44 Vijayalaxmi,Meltz ML,Reiter RJ,et al.Melatonin and protection from genetic damage in blood and bone marrow:Whole-body irradiation studies in mice.[J]Pineal Res 1999,27:221-225
45 Jahnke G,Marr M,Myers C,et al.Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague Dawley rats.[J]Toxicol Sci 1999,50:271-279
46 Kaya H,Delibas N,Serteser M,et al.The effect of melatonin on lipid peroxidation during radiotherapy in female rats.[J]Strahlenther Onkol 1999,175:285-288
47 Miles A,Philbrick D.Melatonin:perspectives in laboratory medicine and clinical research.[J]Crit Rev Cli n L ab Sci,1978,25(3):231-53
48 Lieberman HR,Waldhausser F,Garfield G,et al.Effects of melatonin on human mood and performance.[J]Brain Resl 984,323:201-207
49 Arendt M,Aldhous M,Marks V.Alleviation of jet lag by melatonin:Preliminary results of controlled double-blind trial.Br Med J Clin Res 1986,292:1170
50 Lissoni P,Barni S,Crispino S,et al.Endocrine and immune effects of melatonin therapy in metastatic cancer patients.Eur J Cancer Clin Oncol 1989,25:789-795
51 James SP,Sack DA,Rosenthal NE,et al.Melatonin administration and insomnia.[J].Neuropsychopharmacology 1990,3:19-23
52 Sarnel A,Wegmann AM,Vejvoda M,et al.Influence of melatonin treatment on human circadian rhythmicity before and after a simulated 9-hour shift.[J]Biol Rhythms 1991,6:235-248
53 Voordouw BC,Euser R,Verdonk RE,et al.Melatonin and melatonin-progestin combinations alter pituitary-ovarian function and can inhibit ovulation.[J]Clin Endocrinol Metab 1992,74:108-117
54 Lissoni P,Barni S,Roveli F,et al.Neuroimmunotherapy of advanced solid neoplasm with single evening subcutaneous injection of low-dose interleukin-2 and melatonin:Preliminary results.[J].Eur J Cancer 1993,29:185-189
55 Vijayalaxmi,Reiter RJ,Herman TS,et al.Melatonin and radioprotection from genetic damage:In vivo/in vitro studies with human volunteers.??[J]Mutat Res 1996,371:221-22856 Sebra MLV,Bignotto M,Pinto LR,Jr.,et al.Randomized,double-blind clinical trial,controlled with placebo,of the toxicology of chronic melatonin treatment.[J].Pineal Res.2000;29:193-20057
58 Tan DX,Chen LD,Poeggeler B,et al.Melatonin:A potent,endogenous hydroxyl radical scavenger.[J]Endocrine J 1993,1:57-6059 Vijayalaxmi,Reiter RJ,Meltz ML.Melatonin protects human blood lymphocytes from radiation-induced chromosome damage.[J]Mutat Res 1995,346:23-3160 Vijayalaxmi,Reiter RJ,Sewerynek E,et al.Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin.[J].Radiat Res 1995,143:102-10661 Vijayalaxmi,Reiter J,Leal BZ,et al.Effect of melatonin on mitotic and proliferation indices and sister chromatid exchange in human blood lymphocytes.[J].MutatRes 1996,351:187-19262 Eva Ku¨hlwein,Michael Irwin Melatonin modulation of lymphocyte proliferation and Thl/Th2 cytokine expression.[J]Journal of Neuroimmunology 2001,117:51-5763 Byung Chun Kim a,Bo Sung Shon a,Young Wook Ryoo Melatonin reduces X-ray irradiation-induced oxidativedamages in cultured human skin fibroblasts.[J]Journal of Dermatological Science 2001,26:194-20064 Vijayalaxmi,Russel J.Reiter,Terence S.Melatonin and radioprotection from genetic damage:In vivo/in vitro studies with human volunteers[J]Mutation Research 1996,371:221-22865 Blickenstaff RT,Brandstadter SM,Reddy S,et al.Potential radioprotective agents:1.Homologues of melatonin.[J]Pharm Sci 1994,83:216-21866 Tesoriere L,D'Arpa D,Conti S,et al.Melatonin protects human red cells from oxidative hemolysis:New insights intothe radical-scavenging activity.[J]Pineal Res 1999,27:95-105
67 M Koc,M,Buyukokuroglu,the effect of melatonin on peripheral blood cells during whole body irradiation in rats.[J]Toxicity reduction Wednesday 2001,24:361
68 Erkan Yurtcu a,Yildiz Guney b,Mehmet Ali Ergun Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007,31:1144-1149
69 Miguel Mart(?)n,Manuel Mac(?)as,Josefa Le(?)n.Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria[J]The International Journal of Biochemistry & Cell Biology2002,34:348-357
70 Go¨ksel S_enera,Nermina Jahovicb,Osman Tosuna Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats Life Sciences 2003,74:563-572
71 A.L.Bhatia,Kailash Manda.Study on pre-treatment of melatonin against radiation-induced oxidative stress in mice。Environmental Toxicology and Pharmacology 2004,18:13-20
72 Mornjakovic Z,Alicelebic S,Bilalovic N,et al.Morphometric characteristics of Leydig cells after total irradiation of rats treated with melatonin[J].Med Arh 1998,52:183-184
73 Kim JK,Lee CJ.Effect of exogenous melatonin on the ovarian follicles in irradiated mouse.[J]Mutat Res 2000,449:33-39
74 Kundurovic Z,Scepovic M.Histoenzymological reactions of the thyroid gland in irradiated and previously melatonintreated irradiated rats.[J]Acta Med Jugosl 1989,43:337-347
75 Kundurovic Z,Mornjakovic Z.Morphometric characteristics of thyroid cells in irradiation-stressed rats treated with pinealectomy and melatonin.[J]Med Arch 1992,46:9-10
76 张萱,龚守良等。褪黑素对电离辐射所致C57BL/6J小鼠免疫功能损伤的防护作用。[J]辐射研究与辐射工艺学报。2003,21(3):202-205
77 L.R.BARLOW-WALDEN,R.J.REITER,M.ABE,Melatonin stimulates brain glutathione peroxidase activity.[J]Neurochem.Int.1995,26(5):497-502
78 üLKü üNDE ˇGER1,BELMA GI~.RAY1,A.FARUK ZORLU2,Protective effects of melatonin on the ionizing radiation induced DNA damage in the rat brain.[J]Exp Toxic Pathol 2004,55:379-384
79 Lissoni P,Meregalli S,Nosetto L et al.Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.[J]Oncology,1996,53(1):43-6
80 Seval Yilmaz,Erhan Yilmaz Effects of melatonin and Vitamin E on oxidative-antioxidative status in rats exposed to irradiation.[J]Toxicology.2006,222:1-7
81 Maestroni,G.J.M.,Covacci,V.and Conti,A.Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice.[J]Cancer Res.1994,54,2429-2432
82 Valentina Rapozzi Sonia Zorzet ‘,Marina Comelli.Melatonin decreases bone marrow and lymphatic toxicity in mice bearing TLX5.[J]lmphoma Life Sciencea.1998,63(19)1701-1713
83 Mamdouh M.Anwar,Hussein A.Mahfouz.Potential Protective Effects of Melatonin on Bone Marrow of Rats Exposed to Cytotoxic Drugs.Comp.[J]Biochem.Physiol.1998,119(2):493-501
84 Mahmoud I.Hassan,Maha I.Ahmed,Samark.Kassim.et al.Cis-Platinum-Induced Immunosuppression:Relationship to Melatonin in Human Peripheral Blood Mononuclear Cells.[J]Clinical Biochemistry.1999,32(8):621-626
85 P.DZIEGIEL,Z.JETHON,E.SUDER,M.Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.[J]Exp Toxic Pathol.2002,53:433-439
86 Aysel Guven,Ozlem Yavuz,Meryem Cam,Melatonin protects against epirubicin-induced cardiotoxicity° Acta histochemica.2007,109:52-60
87 Sener,G.,Satiroglu,H.,Kabasakal,L.,The protective effect of melatonin on cisplatin nephrotoxicity.Fundam.Clin.Pharmacol.2000,14:553-560
88 Hara,M,Yoshida,M,Nishijima,H.,Melatonin,a pineal secretory product with antioxidant properties,protects against cisplatin-induced nephrotoxicity in rats.[J].Pineal Res.2001,30:129-138
89 Minoru Yoshidaa,*,Atsushi Fukudaa,Masayuki Hara Melatonin prevents the increase in hydroxyl radical-spin trap adduct formation caused by the addition of cisplatin in vitro[J]Life Sciences 2003,72:1773-1780
90 Badreldin H.Ali a? Mansour S.Al Moundhri Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds:A review of some recent research.[J]Food and Chemical Toxicology 2006,44:1173-1183
91 Junya Fukutomi,Atsushi Fukuda b,Satoshi Fukuda.Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species.Life Sciences 2006,80:254-257
92 Turgut Topala,*,Sukru Otera,Ahmet Korkmaz.Exogenously administered and endogenously produced melatonin reduce hyperbaric oxygen-induced oxidative stress in rat lung.[J]Life Sciences 2004,75:461-467
93 Muharrem Ucar,Ahmet Korkmaz,Russel J.Reiter,Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard Toxicology Letters 2007,173(2):124-131
94 Jem Herrstedt.Prevention and management of mucositis in patients with cancer.Internationalo[J]Journal of Antimicrobial Agents 2000,16:161-163
95 Lissoni P,Barni S,Mandate' M,et al.Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.[J]Eur J Cancer 1999,35:1688-92
96 P.Lissoni.Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.[J]Pathologie Biologie 2007,55(3-4):201-204
97 Keith I.Block,Amanda C.Koch,Mark N.Meado Impact of antioxidant supplementation on chemotherapeutic efficacy:A systematic review of the evidence from randomized controlled trials.[J]Cancer Treatment Reviews 2007,33(5):407-418
1 Uwe D.Rohr,Jens Herold.Melatonin deficiencies in women Maturitas 41 Suppl.1(2002)S85-S104
2 Samuel Cos MD,,Alicia Gonza'lez,Carlos Marti'nez-Campa,Estrogen-signaling pathway:A link between breastcancer and melatonin oncostatic actionsCancer Detection and Prevention 2006(30):118-128
3 Siu SW,Lau KW,Tarn PC,et al.melatonin amd prostate cancer cell proliferation:interplay with castration,epidermal growth factor,and androgen sensitivity.prostate,2002,52(2):106-22
4 Shiu SYW,Li L,Xu JN,et al.Melatonin-induced inhibition of proliferation and Gl/ S cell cycle transition delay of human choriocarcinoma JAr cells:Possible involvement of MT2(MEL1B)receptor.J Pineal Res,1999,27:183-192
5 Mariano Bizzarri,Alessandra Cucina,Maria Giovanna Valente Melatonin and Vitamin D3 Increase TGF-pl Release and Induce Growth Inhibition in Breast Cancer Cell Cultures.[J]Journal of Surgical Research 2003,110:332-337
6 Bruno N,Carlo L,Fausto M,et al.Modulation of human lympholastoid interferona ctivity by melatonin in metastatic renal cell carcinoma.[J]cancer,1994,73(12):3015-3019
7 Huerto-Delgakillo L,Anton-Tay F,Benitez-King G.Effects of melatonin on microtubule assembly depend on hormone concentration:Role of melatonin as a calmodulin antagonist.[J]Pineal Res,1994,17:55-62
8 Erkan Yurtcu,Yildiz Guney,Mehmet Ali Ergun Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes[J]Cell Biology International 2007,31:1144-1149
9 Kojima T,Mochizuki C,Mitaka T,et al.Effects of melatonin on proliferation,oxidative stress and Cx32 gap junction protein expression in primary cultures of adult rat hepatocytes.[J]Cell Struct Funct,1997,22(3):347-56
10 Cos S,Fernandez R,Guezmes A,et al.Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.[J]Cancer Res,1998,58(19):4383-90
11 高列,许荣锟。褪黑素抗肿瘤机制的研究进展。[J]生理科学进展,2001,32(2):160-162
12 Huerto-Delgakillo L,Anton-Tay F,Benitez-King G.Effects of melatonin on microtubule assembly depend on hormone concentration:Role of melatonin as a calmodulin antagonist.[J]Pineal Res,1994,17:55-62
13 D.E.Blask,L.A.Sauer,R.T.Dauchy,E.W.Holowachuk,M.S.Ruhoff,H.S.Kopff,Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.[J]Cancer Res.1999,59:4693-4701
14 Erkan Yurtcu,Yildiz Guney,Mehmet Ali Ergun.et al.Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007,31:1144-1149
15 Anivsimov VN,Popovich IG,Zabezhinski MA.Melatonin and colon carcinogenesis:Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats.[J]Exp Toxic Pathol,2000,52:71-76
16 Conti A,Maestroni GJM.The clinical neuroimmunoltherapeutic role of melatonin in oncology.[J]Pineal Res,1995,19:103-110
17 E.Martins Jr.,L.C.Fernandes,I.Bartol,The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats.[J]Journal of Neuroimmunology。1998.45:8281-89
18 Lissoni P,Tancini G,Rovelli F et al.Serum intedeukin-2 levels in relation to the neuroendocrine status in cancer patients.[J]B r Cancer, 1990,62(5):838-9
19 Conti A,Maestroni GJ.The clinical neuroimmunotherapeutic role of melatonin in oncology.[J]Pineal Res,1995,19(3):103-10
20 Lissoni P,Barni S,Tancini A et al.Neuroimmunomodulation of interlrukin-2 cancer immunotherapy by melatonin:biological and therapeutic results.In:Maestroni GJM,Conti A,Reiter RJ eds.Advance in Pineal Research,London:John Libbey,1994,7:183-9
21 Neri B,Fiorelli C,Moroni F et al.Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma.A phase Ⅱ st udy Cancer,1994,73(12):3015-9
22 Braczkowski R,Zubelewicz B,Romanowski W et al.Modulation of tumor necrosis factor-alpha(TNF-alpha) toxicity by the pineal hormone melatonin(ML T) in metastatic solid tumor patients.[J]A nn N Y Acad Sci,1995,768:334-6
23 Masayuki Futagami,M.D.,Shigemi Sato,M.D.,Tomomi Sakamoto,M.D.et al.Effects of Melatonin on the Proliferation and cis-Diamminedichloroplatinum(CDDP) Sensitivity of Cultured Human Ovarian Cancer Cells.[J]Gynecologic Ontology 2001,82,:544-549
24 王忠强 郑启昌 黄文广等褪黑素、顺铂协同抑制人肝癌细胞SMMC-7721的机制研究[J]华中科技大学学报(医学版)2004,33(5):569
25 Yoshihiko Furuya,Kyousuke Yamamoto,Norio Kohnob,et al.5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells(MCF-7).[J]Cancer Letters.1994,81:95-98
26 Keith I.Block,Amanda C.Koch,Mark N.Mead.Impact of antioxidant supplementation on chemotherapeutic efficacy:A systematic review of the evidence from randomized controlled trials.Cancer Treatment Reviews 2007,33(5):407-418
27 Lissoni P,Barni S,Mandala' M,et al.Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.[J]Eur Cancer 1999,35:1688-92
28 P.Lissoni Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.[J]Pathologie Biologie 2007,(55):201-204
2 Samuel Cos MD,Alicia Gonza'lez,Carlos Mart(?)nez-Campa Estrogen-signaling pathway:A link between breast cancer and melatonin oncostatic actions o[J]Cancer Detection and Prevention 2006,30:118-128
3 Cos S,Blask DE,Lemus-Wilson A,et al.Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture.[J]Pineal Res 1991,10:36-42.
4 蔡晓宏,赵晏,刘鸿。褪黑素对人小细胞肺癌NCIH446细胞的抑制作用.[J]中国药理学通报。2000,16(5):593-594
5 白艳红1,赵晏2,蔡晓宏,褪黑素对人胃腺癌SGC27901细胞的抑制作用。[J]西安医科大学学报。2002,23(2):144-146
6 Morgan PJ,Barrett P,Howell HE,et al.Melatonin receptor:Location molecular pharmacology and physiological significance.[J]Neurochem Int,1994,24:101-146
7 Winczyk K,Pawlikowski M,Lawnicka H,et al.Effect of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-2-yl)methyl]propanamide on murine colon 38 cancer growth in vitro and in vivo.[J]Neuroendocrinol Lett,2002,23(Suppll):50-4
8 段小娴.bcl-2基因家族对细胞凋亡的调控.中国医学文摘.肿瘤学,2001,15(1):80
9 籍敏,王全红.bcl-2在乳腺癌中的表达及意义.[J]山西医科大学学报.2007,38(4):337-338
10 Gee JM,Robertson JF,Ellis IO,et al.Immunocytochemical localization of BCL-2 protein in human breast cancer and its relationship to a series of prognostic markers and response to endocrine therapy.Int J Cancer,1994,59:619-28
11 M.D.Mediavilla,S.Cos and E.J.Sanchez-Barcelo.Melatonin increase P53and p21WAF1 expression in MCF-7 human breast cancer cells in vitro Life Sciences,1999,65(4):415-420
12 孙晓杰,吴琦.细胞凋亡相关基因P53和bcl-2在乳腺癌中的表达.[J]中国现代医学杂志。2002,12(5):72-73
13 Yoo YM,Yim SV,Kim ss,et al.Melatonin suppresses NO-induced apoptosis via induction of Bcl-2 expression in PGT-beta immortalized pineal cells.[J]Pineal Res,2002,33(3):146-150
14 Sainz RM,Mayo JC,Uria H,et al.The pineal neurohormone melatonin prevents in vivo and in invitro apoptosis in thymcytes.[J]Pineal Res,1995,19:178-188
1 Patricia S'anchez-Su'arez,Patricia Ostrosky-Wegman,Francisco Gallegos-Hern'andez,et al.DNA damage in peripheral blood lymphocytes in patients during combined chernotherapy for breast cancer[J].Mutation Research 2008,640(1-2):8-15
2 P.Lissoni.Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms [J].Pathologie Biologic 2007,55(3-4):201-204
3 Go¨ksel Sener,Nermina Jahovic,Osman Tosun,et al,Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats.Life Sciences[J].2003,74(5):563-572
4 Aysel G,Ozlem Y,Meryem C,et al.Melatonin protects against epirubicin-induced cardiotoxicity[J].Acta histochemical 2007,109(1):52-60
5 王忠强,郑启昌,黄文广,等.褪黑素、顺铂协同抑制人肝癌细胞SMMC-7721的机制研究[J].华中科技大学学报(医学版),2004,33(5):569-572
6 吴琛珩,王树人,刘漪沦,等.恶性肿瘤组织的氧化还原态及其抗氧化能力的改变[J].中国病理生理杂志,2005,21(11):2160-2165
7 韩晓群,李著华,王树人,等.细胞内GSH耗竭逆转人乳腺癌耐药细胞株MCF-7/ADM对阿霉素的耐药性[J].四川生理科学杂志,2005;27(4):152-154
8 韩晓群,李著华,张敬各,等.降低细胞内GSH浓度对乳腺癌细胞阿霉素敏感性的影响[J].四川大学学报(医学版),2007;38(5):770-774
9 Albert W,Hans-Christian C,Peter M.A,et al.Prooxidant activity of melatonin promotes fas-induced cell death in human leukemic Jurkat cells[J].FEBS Letters,2001,502(3):127-131
10 Barlow-Walden LR,Reiter RJ,Abe M,et al.Melatonin stimulates brain glutathione peroxidase activity[J].Neurichem Int,1995,26(5):497-502
11 Kumaraguruparan R,Subapriya R,Viswanathan P,et al.Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast[J].Clin Chim Acta,2002,325(1-2):165-170
12 Cullen JJ,Mitros FA,Oberley LW.Expression of antioxidant enzymes in diseases of the human pancreas:another link between chronic pancreatitis and pancreatic cancer[J].Pancreas,2003,26(1):23-27
13 Bostwick DG,Alexander EE,Singh R,et al.Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer[J].Cancer,2000,89(1):123-134
14 Kolanjiappan K,Ramachandran CR,Manoharan S.Biochemical changes in tumor tissues of oral cancer patients[J].Clin Biochem,2003,36(1):61-65
15 Rudin CM,Yang Z,Schumaker LM,et al.Inhibition of glutathione synthesis reverses Bcl-2 mediated cisplatin resistance[J].Cancer Res,2003,63(2):312-318
1 S.R.Teplitzkya,f,T.L.Kiefere,f,Q.Cheng,et al.Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid.[J]Cancer Letters 2001,168:155-163
2 Dagar S,Sekosan M,Rubinstein I,et al.Detection of VIP receptors in MNU-induced breast cancer in rats:implications for breast cancer targeting[J].Breast Cancer Res Treat,2001,65(1):49-54
3 WeiW,Shen YX,DaiM,Chen Q.Effects and mechanisms of melatonin on immune responses in mice of different months[J].Acta Pharmacol Sin,2003,24(7):719-723
4 许建宁,许建平.褪黑素与肿瘤防治的研究进展。国外医学卫生学分册,1999,26(2):78-80
5 Maria P.Jonesa,Melissa A.Melan,et al.Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner.[J].Cancer Letters 2000;151:133-143
6 Ana I.Esquifinoa,S.R.Pandi-Perumalb,et al.Circadian organization of the immune response:A role for melatonin.[J]Clinical and Applied Immunology Reviews 2004,4:423-433
7 周学武,国安,罗春芬,等.褪黑素对大鼠肝缺血再灌注损伤的保护作用研究[J].浙江医学,2006,28(8):642-644
8 Tsuda T,Ide M,Iigo M.Influence of season and of temperature,photoperiod and subcutaneous melatonin infusion on the glomerular filtration rate ofewes.[J].Pineal Res,1995,19:166-172
9 Bubenik GA.Localization,physiological significance and possible clinical implication of gast rointestinal melatonin.[J]Biol Signals Recept,2001,10:350-366
10 周良玉,张钦,康二虎.褪黑素对大鼠肠缺血/再灌注损伤保护作用的实验研究[J].实用医技杂志,2006,13(11):1810-1812
11 李源,郑延松,臧益民。褪黑素对氧化损伤培养心肌细胞的保护作用。[J].第四军医大学学报,2002,23(22),2060-62
12 韦开福,林英忠,马业新.褪黑素对大鼠缺血再灌注后心脏功能的影响[J].右江民族医学院学报,2006,28(6):914-916
13 周文峰,明章银,向继洲.褪黑素对大鼠失血性休克心肌的保护作用及对MEK/ERK通路的影响.[J].医药导报,2007,6(5)469-472
14 P.DZI EGIEL,Z.JETHON,E.SUDER,M.Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.[J]Exp Toxic Pathol.2002,53:433-439
15 Aysel Guven,Ozlem Yavuz,Meryem Cam,Melatonin protects against epirubicin-induced cardiotoxicity.[J]Acta histochemica.2007,109:52-60
16 Josefa Leona,Dario Acun(?)-Castroviejo,et al.Melatonin and mitochondrial function.[J].Life Sciences 2004,75:765-790
17 Cos S,Fern(?)ndez R,G(u|¨)ezmes A,S(?)nchez-Barcel(?)EJ.Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.[J]Cancer Res 1998,58:4383-90
18 Cos S,Fern(?)ndez R.Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells.[J]Pineal Res 2000,29:166-71
19 Garc(?)a-Pedrero JM,del Rio B,Mar(?)nez-Campa C,Muramatsu M,Lazo PS,Ramos S.Calmodulin is a selective modulator of estrogen receptors.[J]Mol Endocrinol 2002,16:947-60
20 Erkan Yurtcu,Yildiz Guney,Mehmet Ali Ergun.et al.Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007,31:1144-1149
1 何炜,李晓晔,石鑫,等.褪黑素的生理活性研究进展[J].医药导报,2006,25(6):556-558
2 Reiter RJ,Guerrero JM,Escames G,et al.Prophylactic actions of melatonin in oxidative neurotoxicity[J].Ann N Y Acad Sci,1997,825(2):70-78
3 Okatani Y,Wakatsuki A,Kaneda C,et al.Melatonin increase activities of glutathione peroxidase and superoxide dismutas in fetal rat brain[J].J Pineal Res,2000,28(2):89-96
4 Pieri C,MarraM,Moroni F,et al.Melatonin protects LDL from oxidation but does not prevent the apolipop rotein derivatization[J].B iochem B iophys Res Comm un,1996,222(2):256-260
5 Mayo JC,Sainz RM,Antolin I,et al.Melatonin regulation of antioxidant enzyme gene expression[J].Cell M ol Life Sci,2002,59(2):1706-1713
6 Rodriguez C,Mayo JC,Sainz RM,et al.Regulation of antioxidant enzymes:A significant role for melatonin[J].J Pineal Res,2004,36(1):1-9
7 Aust S,Thalhammer T,Humpeler S,et al.The melatonin receptor subtype MT 1 is expressed in human gallbladder epithelia[J].J Pineal Res,2004,36(1):43-48
8 Erkan Yurtcu,Yildiz.Guney,Mehmet Ali Ergun.et al.Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007(31)1144-1149
9 Reiter RJ,Acuna-Castroviejo D,Tan DX,et al Mechanisms for the protective actions of melatonin in the central nervous system[J].Ann N Y Acad Sci,2002,895:200 -215
10 GeoffriauM,Brun J,Chazot G,et al.The physiology and pharmacology Of melatonin in humans[J].Horm Res,1998,49(3-4):136-141
11 Konakchieva R,Mitev Y,Almeida OF,et al.Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothlamic-p ituitary-adrenal axis in the rat[J].N euroendocrinology,1998,67(3):171-180
12 Zeitzer JM,AyasNT,Shea SA,et al.Absence of detectable melatonin and p reservation of cortisol and thyrotrop in rhythms in tetrap legia[J].J Clin EndocrinolM etab,2000,85(6):2189-2196
13 LechnerO,Dietrich H,Oliveira SA,et al.Altered circadian rhythms of the stress hormone and melatonin response in lupusp rone MRL /MP fas(Ip r) mice[J].J Autoimmun,2000,14(4):325-333.
14 Kostoglou-Athanassiou I,Treacher DF,WheelerMJ,et al.Melatonin administration and pituitary hormone secreton[J].Clin Endocrinol,1998,48(1):31-37
15 Reiter R J,Tan D X,Terron M P,et al.Melatonin and its metabolites:new findings regarding their production and their radical scavenging actions [J].Acta Biochem Pol,2007,54(1):1291
16 Hardeland R,Pandi-Perumal S R,Cardinali D P.Molecules in focus:Melatonin[J].Int J Biochem Cell Biol,2006,38:313-3161
17 赵浩淼,李作孝,刘广益.褪黑激素与脑保护[J].医学综述,2006,12(10):596-598
18 王东吉,武凡,武延隽 褪黑素对大鼠脑缺血再灌注损伤及胞浆型磷脂酶A2蛋白表达的影响[J]中华老年心脑血管病杂志2007,9(4)272-275
19 李源1,郑延松1,臧益民 褪黑素对氧化损伤培养心肌细胞的保护作用。[J].第四军医大学学报,2002;23(22),2060-62
20 韦开福,林英忠,马业新.褪黑素对大鼠缺血再灌注后心脏功能的影响[J].右江民族医学院学报,2006,28(6):914-916
21 周文峰,明章银,向继洲.褪黑素对大鼠失血性休克心肌的保护作用及对MEK/ERK通路的影响.[J].医药导报,2007,6(5)469-472
22 Rafael Bruck,Hussein Aeed,Yona Avni et al.Melatonin inhibits nuclear factor kappa B activation and oxidativestress and protects against thioacetamide induced liver damage in rats.[J].Journal of Hepatology, 2004,40:86-93
23 周学武,金国安,罗春芬,等.褪黑素对大鼠肝缺血再灌注损伤的保护作用研究[J].浙江医学,2006,28(8):642-644
24 叶根深1,马勇2,魏伟褪黑素对CCl4诱导大鼠肝纤维化模型肝星状细胞凋亡和功能的影响.[J].安徽医科大学学报 2007,42(2):183-185
25 Lang U,Aubert ML,Sizonenko PC.Location of melatonin receptors[J].Paediatr Res,1981,15:80
26 Tsuda T,Ide M,Iigo M.Influence of season and of temperature,photoperiod and subcutaneous melatonin infusion on the glomerular filtration rate of ewes.[J].Pineal Res,1995,19:166-172
27 Daniels WM,Reiter RJ,Melchiorri D,et al.Melatonin counteracts lipid peroxidation induced by carbon tetrachloride but does not restore glucose-6 phosphate activity.[J]Pineal Res,1995,19:1-6
28 Bubenik GA.Localization,physiological significance and possible clinical implication of gast rointestinal melatonin.[J]Biol Signals Recept,2001,10:350-366
29 Sener-Muratoglu G,Paskaloglu K,Arbak S,et al.Protective effect of famotidine,omeprazole,and melatonin against acetylsalicylic acid-induced gastric damage in rat s.[J]Dig Dis Sci,2001,46:318-330
30 Ganguly K,Kundu P,Banerjee A,et al.Hydrogen Peroxidemediated downregulation of mat rix metalloprotease-2 in indomet hacininduced acute gastric ulceration is blocked by melatonin and other antioxidants.[J]Free Radic Biol Med,2006,41:911-925
31 Brzozowski T,Konturek PC,Zwirska-Korczala K,et al.Importance of t he pineal gland,endogenous prostaglandins and sensory nerves in t he gastroprotective actions of cent ral and peripheral melatonin against st ress-induced damage.[J]Pineal Res,2005,39:375-385
32 Brzozowska I,Konturek PC,Brzozowski T,et al.Role of prostaglandins,nitric oxide,sensory nerves and gastrin in acceleration of ulcer healing by melatonin and it s precursor,L-tryptophan.J Pineal Res,2002,32:149-162
33 周良玉,张钦,康二虎.褪黑素对大鼠肠缺血/再灌注损伤保护作用的实验研究[J].实用医技杂志,2006,13(11):1810-1812
34 张慧,张立斌,刘志民.褪黑素对高糖条件下牛主动脉内皮细胞保护作用的实验研究[J].解放军医学杂志.2003,28(3):225-227
35 Wang WZ,Fang XH,Stephenson LL,et al.Microcirculatory effects of melatonin in rat skeletal muscle after prolonged ischemia[J]J Pineal Res.2005,39(1):57-65
36 张慧,张玉西.褪黑素对高糖条件下牛主动脉内皮细胞NO S 活性和iNO S mRNA表达的影响.[J]东南国防医药,2007:9(2)95-97
37 Markowska M,Mrozkowiak A,Pawlak J,Skwarlo-Sonta K.Intracellar second messagers involved in melatonin signal transduction in chicken splenocytes in vitro[J].J Pineal Res,2004,37(3):207-212
38 Wei W,Shen YX,DaiM,Chen Q.Effects and mechanisms of melatonin on immune responses in mice of different months[J].Acta Pharmacol Sin,2003,24(7):719-723
39 Li JH,Yu JP,Yu HG,Xu XM,Yu LL,Liu J,et al.Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in ratswith colitis[J].Mediators Inflamm,2005,31(4):185-193
40 Maestroni GJ.The immunotherapeutic potential of melatonin[J].Expert Op in Investig Drugs,2001,10(3):467-476
41 Moore CB,Siopes TD.Melatonin enhances cellular and humoral immune responses in the Japanese quail(Coturnix coturnix japonica) via an opiatergic mechanism[J].Gen Comp Endocrinol,2003,131(3):258-263
42 Blickenstaff RT,Brandstadter SM,Reddy S,et al.Potential radioprotective agents:1.Homologues of melatonin.[J]Pharm Sci 1994,83:216-218
43 Vijayalaxmi,Meltz ML,Reiter RJ,et al.Melatonin and protection from whole-body irradiation:Survival studies in mice.[J]Mutat Res 1999,425:21-27
44 Vijayalaxmi,Meltz ML,Reiter RJ,et al.Melatonin and protection from genetic damage in blood and bone marrow:Whole-body irradiation studies in mice.[J]Pineal Res 1999,27:221-225
45 Jahnke G,Marr M,Myers C,et al.Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague Dawley rats.[J]Toxicol Sci 1999,50:271-279
46 Kaya H,Delibas N,Serteser M,et al.The effect of melatonin on lipid peroxidation during radiotherapy in female rats.[J]Strahlenther Onkol 1999,175:285-288
47 Miles A,Philbrick D.Melatonin:perspectives in laboratory medicine and clinical research.[J]Crit Rev Cli n L ab Sci,1978,25(3):231-53
48 Lieberman HR,Waldhausser F,Garfield G,et al.Effects of melatonin on human mood and performance.[J]Brain Resl 984,323:201-207
49 Arendt M,Aldhous M,Marks V.Alleviation of jet lag by melatonin:Preliminary results of controlled double-blind trial.Br Med J Clin Res 1986,292:1170
50 Lissoni P,Barni S,Crispino S,et al.Endocrine and immune effects of melatonin therapy in metastatic cancer patients.Eur J Cancer Clin Oncol 1989,25:789-795
51 James SP,Sack DA,Rosenthal NE,et al.Melatonin administration and insomnia.[J].Neuropsychopharmacology 1990,3:19-23
52 Sarnel A,Wegmann AM,Vejvoda M,et al.Influence of melatonin treatment on human circadian rhythmicity before and after a simulated 9-hour shift.[J]Biol Rhythms 1991,6:235-248
53 Voordouw BC,Euser R,Verdonk RE,et al.Melatonin and melatonin-progestin combinations alter pituitary-ovarian function and can inhibit ovulation.[J]Clin Endocrinol Metab 1992,74:108-117
54 Lissoni P,Barni S,Roveli F,et al.Neuroimmunotherapy of advanced solid neoplasm with single evening subcutaneous injection of low-dose interleukin-2 and melatonin:Preliminary results.[J].Eur J Cancer 1993,29:185-189
55 Vijayalaxmi,Reiter RJ,Herman TS,et al.Melatonin and radioprotection from genetic damage:In vivo/in vitro studies with human volunteers.??[J]Mutat Res 1996,371:221-22856 Sebra MLV,Bignotto M,Pinto LR,Jr.,et al.Randomized,double-blind clinical trial,controlled with placebo,of the toxicology of chronic melatonin treatment.[J].Pineal Res.2000;29:193-20057
58 Tan DX,Chen LD,Poeggeler B,et al.Melatonin:A potent,endogenous hydroxyl radical scavenger.[J]Endocrine J 1993,1:57-6059 Vijayalaxmi,Reiter RJ,Meltz ML.Melatonin protects human blood lymphocytes from radiation-induced chromosome damage.[J]Mutat Res 1995,346:23-3160 Vijayalaxmi,Reiter RJ,Sewerynek E,et al.Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin.[J].Radiat Res 1995,143:102-10661 Vijayalaxmi,Reiter J,Leal BZ,et al.Effect of melatonin on mitotic and proliferation indices and sister chromatid exchange in human blood lymphocytes.[J].MutatRes 1996,351:187-19262 Eva Ku¨hlwein,Michael Irwin Melatonin modulation of lymphocyte proliferation and Thl/Th2 cytokine expression.[J]Journal of Neuroimmunology 2001,117:51-5763 Byung Chun Kim a,Bo Sung Shon a,Young Wook Ryoo Melatonin reduces X-ray irradiation-induced oxidativedamages in cultured human skin fibroblasts.[J]Journal of Dermatological Science 2001,26:194-20064 Vijayalaxmi,Russel J.Reiter,Terence S.Melatonin and radioprotection from genetic damage:In vivo/in vitro studies with human volunteers[J]Mutation Research 1996,371:221-22865 Blickenstaff RT,Brandstadter SM,Reddy S,et al.Potential radioprotective agents:1.Homologues of melatonin.[J]Pharm Sci 1994,83:216-21866 Tesoriere L,D'Arpa D,Conti S,et al.Melatonin protects human red cells from oxidative hemolysis:New insights intothe radical-scavenging activity.[J]Pineal Res 1999,27:95-105
67 M Koc,M,Buyukokuroglu,the effect of melatonin on peripheral blood cells during whole body irradiation in rats.[J]Toxicity reduction Wednesday 2001,24:361
68 Erkan Yurtcu a,Yildiz Guney b,Mehmet Ali Ergun Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007,31:1144-1149
69 Miguel Mart(?)n,Manuel Mac(?)as,Josefa Le(?)n.Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria[J]The International Journal of Biochemistry & Cell Biology2002,34:348-357
70 Go¨ksel S_enera,Nermina Jahovicb,Osman Tosuna Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats Life Sciences 2003,74:563-572
71 A.L.Bhatia,Kailash Manda.Study on pre-treatment of melatonin against radiation-induced oxidative stress in mice。Environmental Toxicology and Pharmacology 2004,18:13-20
72 Mornjakovic Z,Alicelebic S,Bilalovic N,et al.Morphometric characteristics of Leydig cells after total irradiation of rats treated with melatonin[J].Med Arh 1998,52:183-184
73 Kim JK,Lee CJ.Effect of exogenous melatonin on the ovarian follicles in irradiated mouse.[J]Mutat Res 2000,449:33-39
74 Kundurovic Z,Scepovic M.Histoenzymological reactions of the thyroid gland in irradiated and previously melatonintreated irradiated rats.[J]Acta Med Jugosl 1989,43:337-347
75 Kundurovic Z,Mornjakovic Z.Morphometric characteristics of thyroid cells in irradiation-stressed rats treated with pinealectomy and melatonin.[J]Med Arch 1992,46:9-10
76 张萱,龚守良等。褪黑素对电离辐射所致C57BL/6J小鼠免疫功能损伤的防护作用。[J]辐射研究与辐射工艺学报。2003,21(3):202-205
77 L.R.BARLOW-WALDEN,R.J.REITER,M.ABE,Melatonin stimulates brain glutathione peroxidase activity.[J]Neurochem.Int.1995,26(5):497-502
78 üLKü üNDE ˇGER1,BELMA GI~.RAY1,A.FARUK ZORLU2,Protective effects of melatonin on the ionizing radiation induced DNA damage in the rat brain.[J]Exp Toxic Pathol 2004,55:379-384
79 Lissoni P,Meregalli S,Nosetto L et al.Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.[J]Oncology,1996,53(1):43-6
80 Seval Yilmaz,Erhan Yilmaz Effects of melatonin and Vitamin E on oxidative-antioxidative status in rats exposed to irradiation.[J]Toxicology.2006,222:1-7
81 Maestroni,G.J.M.,Covacci,V.and Conti,A.Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice.[J]Cancer Res.1994,54,2429-2432
82 Valentina Rapozzi Sonia Zorzet ‘,Marina Comelli.Melatonin decreases bone marrow and lymphatic toxicity in mice bearing TLX5.[J]lmphoma Life Sciencea.1998,63(19)1701-1713
83 Mamdouh M.Anwar,Hussein A.Mahfouz.Potential Protective Effects of Melatonin on Bone Marrow of Rats Exposed to Cytotoxic Drugs.Comp.[J]Biochem.Physiol.1998,119(2):493-501
84 Mahmoud I.Hassan,Maha I.Ahmed,Samark.Kassim.et al.Cis-Platinum-Induced Immunosuppression:Relationship to Melatonin in Human Peripheral Blood Mononuclear Cells.[J]Clinical Biochemistry.1999,32(8):621-626
85 P.DZIEGIEL,Z.JETHON,E.SUDER,M.Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.[J]Exp Toxic Pathol.2002,53:433-439
86 Aysel Guven,Ozlem Yavuz,Meryem Cam,Melatonin protects against epirubicin-induced cardiotoxicity° Acta histochemica.2007,109:52-60
87 Sener,G.,Satiroglu,H.,Kabasakal,L.,The protective effect of melatonin on cisplatin nephrotoxicity.Fundam.Clin.Pharmacol.2000,14:553-560
88 Hara,M,Yoshida,M,Nishijima,H.,Melatonin,a pineal secretory product with antioxidant properties,protects against cisplatin-induced nephrotoxicity in rats.[J].Pineal Res.2001,30:129-138
89 Minoru Yoshidaa,*,Atsushi Fukudaa,Masayuki Hara Melatonin prevents the increase in hydroxyl radical-spin trap adduct formation caused by the addition of cisplatin in vitro[J]Life Sciences 2003,72:1773-1780
90 Badreldin H.Ali a? Mansour S.Al Moundhri Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds:A review of some recent research.[J]Food and Chemical Toxicology 2006,44:1173-1183
91 Junya Fukutomi,Atsushi Fukuda b,Satoshi Fukuda.Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species.Life Sciences 2006,80:254-257
92 Turgut Topala,*,Sukru Otera,Ahmet Korkmaz.Exogenously administered and endogenously produced melatonin reduce hyperbaric oxygen-induced oxidative stress in rat lung.[J]Life Sciences 2004,75:461-467
93 Muharrem Ucar,Ahmet Korkmaz,Russel J.Reiter,Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard Toxicology Letters 2007,173(2):124-131
94 Jem Herrstedt.Prevention and management of mucositis in patients with cancer.Internationalo[J]Journal of Antimicrobial Agents 2000,16:161-163
95 Lissoni P,Barni S,Mandate' M,et al.Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.[J]Eur J Cancer 1999,35:1688-92
96 P.Lissoni.Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.[J]Pathologie Biologie 2007,55(3-4):201-204
97 Keith I.Block,Amanda C.Koch,Mark N.Meado Impact of antioxidant supplementation on chemotherapeutic efficacy:A systematic review of the evidence from randomized controlled trials.[J]Cancer Treatment Reviews 2007,33(5):407-418
1 Uwe D.Rohr,Jens Herold.Melatonin deficiencies in women Maturitas 41 Suppl.1(2002)S85-S104
2 Samuel Cos MD,,Alicia Gonza'lez,Carlos Marti'nez-Campa,Estrogen-signaling pathway:A link between breastcancer and melatonin oncostatic actionsCancer Detection and Prevention 2006(30):118-128
3 Siu SW,Lau KW,Tarn PC,et al.melatonin amd prostate cancer cell proliferation:interplay with castration,epidermal growth factor,and androgen sensitivity.prostate,2002,52(2):106-22
4 Shiu SYW,Li L,Xu JN,et al.Melatonin-induced inhibition of proliferation and Gl/ S cell cycle transition delay of human choriocarcinoma JAr cells:Possible involvement of MT2(MEL1B)receptor.J Pineal Res,1999,27:183-192
5 Mariano Bizzarri,Alessandra Cucina,Maria Giovanna Valente Melatonin and Vitamin D3 Increase TGF-pl Release and Induce Growth Inhibition in Breast Cancer Cell Cultures.[J]Journal of Surgical Research 2003,110:332-337
6 Bruno N,Carlo L,Fausto M,et al.Modulation of human lympholastoid interferona ctivity by melatonin in metastatic renal cell carcinoma.[J]cancer,1994,73(12):3015-3019
7 Huerto-Delgakillo L,Anton-Tay F,Benitez-King G.Effects of melatonin on microtubule assembly depend on hormone concentration:Role of melatonin as a calmodulin antagonist.[J]Pineal Res,1994,17:55-62
8 Erkan Yurtcu,Yildiz Guney,Mehmet Ali Ergun Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes[J]Cell Biology International 2007,31:1144-1149
9 Kojima T,Mochizuki C,Mitaka T,et al.Effects of melatonin on proliferation,oxidative stress and Cx32 gap junction protein expression in primary cultures of adult rat hepatocytes.[J]Cell Struct Funct,1997,22(3):347-56
10 Cos S,Fernandez R,Guezmes A,et al.Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.[J]Cancer Res,1998,58(19):4383-90
11 高列,许荣锟。褪黑素抗肿瘤机制的研究进展。[J]生理科学进展,2001,32(2):160-162
12 Huerto-Delgakillo L,Anton-Tay F,Benitez-King G.Effects of melatonin on microtubule assembly depend on hormone concentration:Role of melatonin as a calmodulin antagonist.[J]Pineal Res,1994,17:55-62
13 D.E.Blask,L.A.Sauer,R.T.Dauchy,E.W.Holowachuk,M.S.Ruhoff,H.S.Kopff,Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.[J]Cancer Res.1999,59:4693-4701
14 Erkan Yurtcu,Yildiz Guney,Mehmet Ali Ergun.et al.Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes.[J]Cell Biology International 2007,31:1144-1149
15 Anivsimov VN,Popovich IG,Zabezhinski MA.Melatonin and colon carcinogenesis:Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats.[J]Exp Toxic Pathol,2000,52:71-76
16 Conti A,Maestroni GJM.The clinical neuroimmunoltherapeutic role of melatonin in oncology.[J]Pineal Res,1995,19:103-110
17 E.Martins Jr.,L.C.Fernandes,I.Bartol,The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats.[J]Journal of Neuroimmunology。1998.45:8281-89
18 Lissoni P,Tancini G,Rovelli F et al.Serum intedeukin-2 levels in relation to the neuroendocrine status in cancer patients.[J]B r Cancer, 1990,62(5):838-9
19 Conti A,Maestroni GJ.The clinical neuroimmunotherapeutic role of melatonin in oncology.[J]Pineal Res,1995,19(3):103-10
20 Lissoni P,Barni S,Tancini A et al.Neuroimmunomodulation of interlrukin-2 cancer immunotherapy by melatonin:biological and therapeutic results.In:Maestroni GJM,Conti A,Reiter RJ eds.Advance in Pineal Research,London:John Libbey,1994,7:183-9
21 Neri B,Fiorelli C,Moroni F et al.Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma.A phase Ⅱ st udy Cancer,1994,73(12):3015-9
22 Braczkowski R,Zubelewicz B,Romanowski W et al.Modulation of tumor necrosis factor-alpha(TNF-alpha) toxicity by the pineal hormone melatonin(ML T) in metastatic solid tumor patients.[J]A nn N Y Acad Sci,1995,768:334-6
23 Masayuki Futagami,M.D.,Shigemi Sato,M.D.,Tomomi Sakamoto,M.D.et al.Effects of Melatonin on the Proliferation and cis-Diamminedichloroplatinum(CDDP) Sensitivity of Cultured Human Ovarian Cancer Cells.[J]Gynecologic Ontology 2001,82,:544-549
24 王忠强 郑启昌 黄文广等褪黑素、顺铂协同抑制人肝癌细胞SMMC-7721的机制研究[J]华中科技大学学报(医学版)2004,33(5):569
25 Yoshihiko Furuya,Kyousuke Yamamoto,Norio Kohnob,et al.5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells(MCF-7).[J]Cancer Letters.1994,81:95-98
26 Keith I.Block,Amanda C.Koch,Mark N.Mead.Impact of antioxidant supplementation on chemotherapeutic efficacy:A systematic review of the evidence from randomized controlled trials.Cancer Treatment Reviews 2007,33(5):407-418
27 Lissoni P,Barni S,Mandala' M,et al.Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.[J]Eur Cancer 1999,35:1688-92
28 P.Lissoni Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.[J]Pathologie Biologie 2007,(55):201-204